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CONTROLLED DELIVERY OF TGF-β1 FROM PLGA NANOPARTICLES
PRATIK VAIDYA
ABSTRACT
Abdominal aortic aneurysms (AAAs) typically manifest as localized wall weakening and dilation
of the infrarenal aorta, which grows gradually, and ultimately leads to fatal rupture. It is caused
due to overexpression of proteolytic enzymes (matrix metalloproteases or MMPs) resulting into
disruption of tissue structure, especially elastic matrix, which cannot be regenerated by adult
vascular cells. On account of post-operative complications associated with their surgical repair,
there is a critical need for developing non-surgical strategies for slowing and even regressing
AAA growth. Recent studies in our laboratory have demonstrated that 1 ng/mL of transforming
growth factor-β1 (TGF-β1) enhances regenerative repair by stimulating elastogenesis in healthy
and aneurysmal rat aortic smooth muscle cell (SMC) cultures. The purpose of this study is to
develop and characterize a nanoparticulate delivery system for localized, controlled and
sustained delivery of TGF-β1 to AAA tissue, for the elastogenic induction of SMCs.
Accordingly, in this study, we have developed TGF-β1 loaded poly (lactic-co-glycolic acid)
PLGA nanoparticles using double-emulsion/solvent evaporation method. The NPs exhibited
sustained release of TGF-β1 over a period of at least 21 days in an in vitro aqueous system. The
released TGF-β1 from NPs inhibited the proliferation of mink lung epithelial cells, which
confirmed the bio-functionality of TGF-β1 protein post-encapsulation. Additionally, our IF
studies demonstrated better fiber formation and orientation of elastin in TGF-β1 NP treated
cultures, which was potentially due to up-regulated expression of structural proteins like collagen
and fibrillin-1 in TGF-β1 treated cultures, as demonstrated by quantitative and qualitative
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studies. Our studies also demonstrated up-regulated levels of lysyl oxidase (LOX), protein
enzyme responsible for cross-linking elastin molecules into fibers in smooth muscle cell (SMC)
extracellular matrix. However, quantitative analysis of insoluble and soluble elastin in TGF-β1
NP treated cultures did not show its up-regulation, which is attributable to lower levels of TGFβ1 (about 1/10th) released in aneurysmal rat SMC (EaRASMC) cultures, compared to our
previously identified elastogenic doses. Nevertheless, this study carries high potential of clinical
translation in future and could evolve as a method to regress AAAs versus current invasive
methods.
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CHAPTER I
INTRODUCTION

1.1

Significance and current treatment of Abdominal Aortic Aneurysms (AAAs)
Aortic aneurysms (AAs) represent localized wall weakening and dilation of the aorta due

to disruption of tissue structure, typically secondary to trauma, infection, atherosclerosis,
vascular hypertension, and overexpression of proteolytic enzymes [1]. If untreated, AAAs can
gradually distend to fatal rupture [2]. Depending on their incidence on the aorta, AAs are
classified as abdominal aortic aneurysms (AAAs), thoraco-abdominal aortic aneurysms, or
thoracic aortic aneurysms (TAAs). AAAs occur in the region between the renal and iliac
bifurcations of the aorta, are typically asymptomatic, and are often detected only when
ultrasound or MRIs are presumptively performed to screen for the condition [3]. The condition is
most common in senior males (>70) in the United States and causes up to 15,000 deaths per year
[4]. Studies have shown that there is low prevalence of AAAs in women compared to men, but
women with smoking history and/or heart disease are at equally high risk of AAA occurrence
[5].
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AAAs are caused due to the fragmentation of elastin and elastic fibers by proteolytic
enzymes called matrix metalloproteinases (MMPs), which are released by inflammatory cells
infiltrating the AAA site following an initial injury or stimulus (e.g., smoking, vasculitis, chronic
hypertension etc) [1, 6, 7]. Currently, open surgical repair and endovascular aneurysmal repair
(EVAR) are surgical, and the only means of AAA repair [8]. Open repair is highly invasive, and
involves abdominal laparotomy, followed by surgical removal of the dilated aorta and its
replacement with Teflon graft [9]. EVAR is a minimally-invasive procedure involving
percutaneous access to the affected area and placement of a stent graft to flow-exclude the AAA
region and prevent further dilatation [10]. High mortality rate due to surgical complications, graft
issues pertaining to lack of biocompatibility, occurrence of endoleaks, and migrating stent grafts,
and inability of aged individuals to withstand surgical procedures can be problematic and
frequently entail the need for surgical re-intervention [11]. Considering these limitations of
surgical AAA repair, there is a critical necessity for novel, non-surgical methods to treat and
potentially prevent AAAs.
Currently there are no non-surgical means to treat AAAs. Considering the fact that the
disruption or loss of elastin and elastic matrix is a critical component of AAA progression, its
repair and/or regeneration offers a promising modality for potentially stabilizing or even
regressing AAA growth. However, the process of elastin synthesis and matrix assembly is highly
complex, and is particularly limited in adult tissues by the inherent deficiency of adult vascular
smooth muscle cells (SMCs) in synthesizing elastin and assembling it into matrix superstructures
(e.g., fibers and fibrous sheets). Additionally, the disruption of elastin/elastic fibers by
proteolytic enzymes (MMPs) overexpressed
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at sites of vascular tissue injury or

disease/inflammation are also hurdles to efficient regeneration of elastic matrix, and their net
accumulation via this process.
Recently, strategies to preserve and stabilize existing elastic matrix within AAAs have
been investigated, which involve suppression of MMP over-production and over-activity within
AAAs. These have included delivery of pharmacological agents (e.g., doxycycline or DOX) [12,
13], tissue inhibitors of matrix metalloproteinases (TIMPs) [14], and the inhibition of
transcription factors mediating mRNA expression for MMPs [15]. Nevertheless, these strategies
have been limited by their potential ability to only slow AAA growth, or at best, not
demonstrated to date, arrest AAA growth, but not regress the AAA towards a healthy state. To
achieve the latter, active regenerative repair of elastic matrix and net new elastic matrix
accumulation is mandated.

1.2

Matrix regenerative therapies
Approaches pertinent to tissue engineering and it’s in vivo counterpart, regenerative

medicine approaches, have gained popularity in combining cells, biomolecules, scaffolds and
dynamic culture approaches to regenerate or restore the function of diseased or structurallydisrupted tissues. Prior studies have identified various biomolecules that stimulate the process of
cellular elastic matrix assembly in vitro. For example, our laboratory has shown the elastogenic
effects of transforming growth factor β1 (TGF-β1) [16], insulin-like growth factor-1 (IGF-1) [17]
and hyaluronan oligomers (HA-o) [16, 17] in healthy [17] and aneurysmal SMC cultures [16,
17]. One way TGF-β1 is hypothesized to enhance elastic matrix regeneration is by up-regulating
lysyl oxidase (LOX) mRNA expression and protein synthesis, leading to increased crosslinking
of elastin precursor molecules towards enhancing elastic fiber assembly [18]. TGF-β1 also is
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known to down-regulate MMP-2 and -9 mRNA expression /protein synthesis in a dose specific
manner [18, 19]. Our lab previously showed 1.0 ng/mL of TGF-β1 dose to significantly upregulate elastin matrix synthesis by vascular SMCs (rat and human) [16, 17].

1.3

Localized, controlled delivery of elastogenic agents within AAAs
While TGF-β1 has pro-elastogenic effects, it is important to note that excessively high

TGF-β1 doses or their systemic delivery in vivo could have adverse effects. For example, it has
been shown that at very high doses, TGF-β1 causes osteogenic differentiation of SMCs and
enhances matrix calcification [16, 20]. Also TGF-β1 over expression which has shown to
stabilize AAAs [21], is known to initiate TAAs [22], common in Marfan syndrome patients [22,
23]. Therefore for in vivo AAA therapy, it is essential to ensure a localized, controlled and
sustained delivery of therapeutic agents such as TGF-β1 via suitable carrier. This thesis project is
focused on the design and development of polymeric nanoparticles (NPs) using poly (lactide-coglycolide) (PLGA) for the encapsulation and localized and controlled/predictable delivery of
TGF-β1 to AAAs in enhancing elastin synthesis. In this study, we evaluate efficacy of these NPs
and the ability of the released agent to influence elastic matrix deposition in vitro aneurysmal
SMC cultures.

1.4

Project goals and specific aims
As discussed in previous sections, this project seeks to achieve elastogenic induction of

aneurysmal rat aortic smooth muscle cells (EaRASMCs) in 2-dimensional (2-D) cultures, via
controlled, sustained delivery of TGF-β1 from PLGA nanoparticles. More specifically, we aim
to:
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•

Specific Aim 1: Design and formulate PLGA NPs encapsulating TGF-β1 and determine
their release characteristics as a function of TGF-β1 loading.

•

Specific Aim 2: Evaluate functional effects of TGF-β1 released from NPs on elastic
matrix deposition in 2-D cultures of EaRASMCs.

1.5

Organization of Thesis
Chapter 2 presents detailed background information on the extracellular matrix (ECM)

components of blood vessels, the structural and biological roles of elastin, and the process of its
synthesis and assembly into a matrix. The chapter further discusses AAAs patho-physiology
towards understanding the critical role played by the loss/degradation of elastin in AAA
progression. Finally, the rationale for the use of, and basis for the development and design of
polymeric nanoparticles for localized, controlled, and long-term delivery of elastogenic factors
for elastogenic induction of SMCs, is elucidated.
Chapter 3 describes the materials and methods employed in fabricating PLGA
nanoparticles encapsulating TGF-β1, the experimental design, and details on specific assays
performed to characterize NPs, their release of TGF-β1, to evaluate TGF-β1 bioavailability and
bioactivity, as well as its in vitro elastogenic effects in 2D cell culture systems.
The results from these assays are discussed in Chapter 4, providing critical insights into
the optimization of TGF-β1 encapsulation and release, and its subsequent effects on enabling the
elastogenic induction of aneurysmal SMCs in vitro.
Finally, Chapter 5 provides perspectives on the results obtained and suggest possible
directions in which the research can be focused, towards developing targeted AAA therapies.
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CHAPTER II
BACKGROUND

2.1

Anatomy of blood vessel
The vascular wall is composed of three concentric layers proceeding outwards from the

lumen; these are the tunica intima, tunica media and tunica adventitia. These layers play critical
roles in determining the structure and function of blood vessels, and contain characteristic cell
types and extra cellular matrix (ECM).

Figure 2.1 Schematic of Ultra Structure of a Blood Vessel [24]
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2.1.1

Tunica intima
The tunica intima forms the innermost layer of a blood vessel, which is directly in contact

with blood flow. It consists of axially-oriented endothelial cells (ECs) and a basement membrane
which is typically composed of loose connective tissue. The basement membrane is comprised of
type IV collagen, laminin, entactin and proteoglycans (heparan sulfate) [25, 26] and adjoins the
internal elastic lamina [26]. The basal lamina acts as a molecular barrier between the endothelial
layer and the underlying mass of connective tissue. The ECs are an integral part of the vessel
wall, playing a critical role in attenuating thrombosis, modulating angiogenesis, and regulating
blood pressure by signaling underlying smooth muscle cells (SMCs), by release of endothelium
derived relaxing factor (EDRF) now identified as nitric oxide (NO) [27]. In addition, the ECs
serve as a barrier to prevent/limit free diffusion of cells and blood fluids/proteins [28]. They also
influence cell polarity, proliferation and differentiation by binding various growth factors (GFs)
and regulate cell metabolism [28, 29].

2.1.2

Tunica media
As the name suggests, this layer is the middle layer of the vascular wall, and in large

elastic vessels (e.g., aorta) is bound on the intimal side by the internal elastic lamina, and on the
adventitial side by the external elastic lamina. The tunica media is predominantly composed of
SMCs and sheets composed of closely enmeshed elastic fibers arranged in concentric alternating
bundles (lamellae) [30]. The SMCs are responsible for the synthesis of elastin molecules that
compose elastic fibers, which then assemble/organize into lamellae. The type and function of the
blood vessel determines the number of elastic lamellae; for example, conduction arteries like the
aorta possess 40-70 lamellar layers whereas peripheral and other arteries are known to contain 3-

7

40 layers [31]. The elastic lamellae are surrounded by sheaths of collagen I, III, V fibers. On
account of the significant amount of elastin fibers and elastic matrix present in this layer, this
layer plays a critical role in the recoil of blood vessels following stretch imposed by flow of
blood pumped out by the heart during cardiac systole.

2.1.3

Tunica adventitia
The tunica adventitia is the outermost layer of the vessel and consists of a collagenous

ECM, terminal nerve fibers, and surrounding connective tissue containing fibroblasts [32]. This
fibrous, collagen-rich layer (mostly collagen types I and III in aortae) prevents vessel over
expansion due to stretch imposed by high luminal blood pressure [33]. Additionally, the
adventitia helps innervate the SMCs in the tunica media, supplies blood to the vessel tissue itself
through a network of capillaries called vasa vasora, so as to maintain cell viability within, and
also to protect the blood vessel from surrounding tissues [34].

2.2

Components of the vascular ECM

2.2.1

Collagen
Collagen is a structural protein abundantly found in blood vessels, comprising

approximately 70% by dry weight in the aorta [35]. Collagen fibers are primarily responsible for
providing support and tensile strength to the vessel [36]. At the molecular level, collagen has a
triple helix of two identical α1-polypeptide chains, with a slightly different α2 chain, and has an
amino acid composition that predominantly contains glycine, proline and hydroxyproline.
Collagen types I, III and V participate in fiber formation. Types I and III are the predominant
types of collagen found in vasculature [37]. Type V collagen is associated with types I and III
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and serves to regulate collagen fiber formation and connect the basement membrane to the
underlying ECM [37]. In addition to its structural role, collagen is also involved in promoting
cell differentiation and attachment [38], and further serves to modulate SMC phenotype,
promoting a more contractile, quiescent phenotype.

2.2.2

Glycoproteins
Fibronectin and laminin are glycoproteins (i.e., biomolecules composed of proteins and

carbohydrates) that are vital to vascular homeostasis, but are not as abundant as collagen in the
matrix. Unlike collagen, they do not perform structural roles but serve to interact with cells via
integrin receptors to modulate their behavior, and also facilitate their interaction with other major
ECM components [39]. Fibronectin is a high molecular weight glycoprotein (~440kDa) that
binds to receptor proteins spanning the cell membrane (integrins) and to the ECM. It can also
specifically bind to other molecules such as collagen and fibrin. It has an important role in matrix
deposition [40] and coagulation [41], as well as in the activation and migration of inflammatory
cells [42]. Laminin is a major protein found in the basal lamina and is associated with type IV
collagen networks. It binds to cell membranes through integrins and other plasma membrane
molecules to contribute to cell attachment, differentiation, cell phenotype and movement [43,
44]. Thus, glycoproteins play an important role in ECM formation and deposition and various
cell processes.

2.2.3

Proteoglycans (PGs) and glycosaminoglycans (GAGs)
PGs and GAGs constitute the amorphous ground substance surrounding vascular cells.

PGs are complex macromolecules that contain a core protein covalently bound to at least one
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GAG chain. They are functionally associated with collagen and elastic fibers in the ECM [45],
binding cations and water due to their anionic groups, and regulating the movement of molecules
through the matrix assembly. GAGs (such as hyaluronan, chondroitin sulfate, dermatan sulfate
and keratan sulfate) are long unbranched polysaccharides consisting of a repeating disaccharide
unit (see Figure 2.2). This repeat unit consists of a hexose (six–carbon sugar) or hexuronic acid
bound to a hexosamine. The availability of sulfate groups and carboxylate groups on their uronic
acids residues imparts an overall negative charge to the molecules themselves. These
polysaccharides bind water to become highly hydrated gel-like structures that resist compressive
forces while permitting rapid diffusion of nutrients, metabolites, and hormones between blood
and tissue [45] .

Figure 2.2 Structure of a GAG, hyaluronic Acid [46]

2.3

Elastin – Biological and structural roles
Elastin is a major structural protein in the ECM of elastic tissues such as large blood

vessels, vocal folds, skin, vaginal wall, lungs and bladder. It is primarily synthesized by SMCs
[47], as well as fibroblasts [48]. In the aorta, elastin contributes to about 50% of tissue dry
weight [49]. In the tunica media, elastin protein is incorporated into and organized as fibers and
sheets (lamellae) which are circumferentially arranged, forming alternating layers with SMCs
[30]. The general organization of elastin in the ultrastructure of blood vessels could either be
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singular or networked mesh-like fibers or non-fibrillar matrix structures like sheets [50], as
shown in Figure 2.3.

Figure 2.3 Scanning electron microscopy (SEM) images showing possble elastic matrix
superstructural forms [50]

2.3.1

Biosynthesis of elastin and the elastic matrix assembly process
The process of elastic matrix assembly is highly complex, and occurs primarily during

fetal development, and the neonatal stage [51]. In most tissues, with certain exceptions (e.g.,
skin) the process of matrix assembly and maturation shows slow down following adolescence. In
brief, elastin is synthesized by SMCs in the vessel wall as a precursor molecule (tropoelastin;
MW = 72 kDa), a hydrophobic protein containing a highly conserved amino acid sequence (ValGly-Val-Ala-Pro-Gly), rich in glycine (33%) and proline (10%). In addition, the protein contains
amino acids such as hydroxyproline (1%), and alanine, valine and leucine (collectively 40-50%)
[52]. The elastin binding protein (EBP) present on the outer plasma membrane of SMCs binds to
tropoelastin, extruded from the intracellular space, and protects it from degradation [53, 54],
while prompting their nucleation and cross-linking. Subsequently, the nuclei interact with a
microfibrillar network of glycoproteins, when the nuclei of tropoelastin molecules dissociate
from their complex with the EBP. These microfibrils, of which fibrillin-1 forms the major
component, are highly aligned and play a crucial role in the coalescence of tropoelastin nuclei to
11

form amorphous elastin deposits [55]. In particular, fibulin-4 and fibulin-5 have been
demonstrated to mediate tropoelastin interactions with the microfibril network [56]. The role of
fibulin-2 in the elastic matrix assembly process, however, is less clear, as one study has
suggested that it works co-operatively with fibulin-5 [57], while another study ruled out its role
in the process [56]. Adjacent elastin molecules are then further cross-linked by a copper
dependent enzyme lysyl oxidase (LOX) and the deposits gradually extended to form mature
elastin fibers [58].

Figure 2.4 Elastic fiber assembly schematic [59]

LOX deaminates lysines in tropoelastin molecules, which then become covalently bound
via desmosine and isodesmosine crosslinks to form the elastic fibers. The mature elastin fibers
thus consist of a central core of cross-linked elastin surrounded by a network of aligned
microfibrils containing fibrillin-1 as a major component [60, 61]. These fibers typically range in
diameter from 300 nm to greater than 1 µm [60, 61]. The elastin fibers along with the highly
aligned microfibrillar scaffold play a critical role in the mechanics and function of the tissue, and
12

impairment in either of these components or in any of the matrix assembly steps may lead to
changes in tissue function and mechanics.

2.3.2

Malfunctions in the elastic matrix assembly process
On account of the complexity of elastogenesis mentioned above and the poor elastogenic

capacity by adult cell types, the generation and/or regeneration of elastin and elastic matrix
structures by healthy or diseased SMCs is problematic in vascular context, the primary challenge
as mentioned, lies in inherently poor elastogenicity of adult vascular SMCs due to continuous
decrease in expression of elastin producing mRNA [62, 63]. In addition, poor cellular ability to
recruit and cross-link elastin precursors into elastic fibers/matrix, are major hurdles to assembly
of elastic matrices. The over-expression of proteolytic enzymes by diseased/activated SMCs and
inflammatory cells recruited to diseased/injured tissue sites also cause significant matrix
disruption [64]. Collectively, these two processes are primarily responsible for the inability of
cells in adult tissues to achieve net accumulation of mature, cross-linked and structurally
appropriate elastic matrix, especially since elastin synthesis and assembly is insufficient relative
to its degradation.
In addition to inherent deficiencies in elastogenesis, related to the aging process,
syndromic disorders can further compromise elastin synthesis and matrix assembly. For
example, genetic disorders such as Marfan syndrome involve mutation of a gene that encodes for
fibrillin-1 which is major component of microfibrils having a role in elastin fiber formation [65].
As a result, poor or lack of deposition of elastin matrix, early fragmentation of elastic fibers
and/or accumulation of amorphous elastin occurs in the tunica media of aortic walls. Patients
with William-Beuren syndrome (WBS) suffer from arterial stenosis and hypertension (leading
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into AAA) as a result of a deleted allele in elastin (ELN) forming gene. As a result of this,
production of tropoelastin is affected which leads to incomplete formation of elastic fibers
altogether, and far fewer elastic lamellae within the aortic wall [66]

2.3.3

Cellular interactions with tropoelastin
In addition to being incorporated into elastic fibers, tropoelastin influences chemotaxis

[67] and adhesion [68] of fibroblasts, while also being shown to stimulate vasodilation and
regulate intracellular Ca2+in vascular ECs and SMCs [69]. These cellular responses are suspected
to elicit feedback control during elastogenesis [70]. Mature elastin has numerous effects on
vascular SMCs including inducing actin stress fiber orientation, inhibiting SMC proliferation and
regulating cell migration, and maintaining SMCs in a healthy quiescent phenotype [71]. It has
been proposed that in vascular SMCs, elastin activates a G-protein coupled pathway that further
downstream inhibits adenylate cyclase and reduces cAMP (inhibitor of elastin synthesis) levels
[72].
SMC interactions with intact elastin also mediate their survival, phenotype, proliferation,
migration and differentiation [73]. For example, SMCs switch from contractile phenotype to a
more synthetic phenotype under pathologic conditions wherein elastin tends to get fragmented
[74, 75]. It has been shown that native elastin promotes hyperproliferation of vascular SMCs and
also controls their differentiation [73]. Studies have shown that elastin controls the proliferation
rate of SMCs and its aggressive migration in response to chemoattractants [74, 76].
As mentioned earlier, under pathologic conditions, elastin is broken down by enzymes to
generate elastin peptides at an accelerated rate, which upregulate SMC proliferation and
activation of phagocytic cells [70]. These elastin peptides interact with cells (e.g., SMCs,
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macrophages) to elicit biological effects such as matrix metalloproteinase (MMP)
overexpression, greater Ca2+ influx, enhanced vasorelaxation and chemotactic activity [74],
which can then lead to undesirable outcomes such as vascular calcification, and enhanced matrix
proteolysis.

Figure 2.5 Schematic showing adverse effects by breakdown of elastic matrix on SMCs [74]

2.4

Proteolytic Disease: Abdominal Aortic Aneurysm (AAAs)

2.4.1

Etiology of AAAs
Aortic aneurysms are progressive, localized expansions of the aorta caused by

pathological weakening of the vessel wall that may have final outcomes of dissections (tears) and
fatal rupture. Abdominal aortic aneurysms (AAAs) occur in the descending aorta below
diaphragm between the infra-renal and iliac bifurcations. The primary risk factors for AAA
development are smoking, atherosclerosis, chronic hypertension, and certain inherited AAAs can
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also occur secondary to vascular infection and inflammation (vasculitis) or abdominal trauma [1,
6, 7, 77]. The fatality rate for this condition is approximately 15,000 deaths per year [4]
In particular, elderly Caucasian men have been identified to represent a high risk
population for AAA development, with incidence in nearly 2-6% of individuals in this
demographic [78].

Figure
2.6
Location
of
AAA
in
human
anatomy
(Adapted
http://www.vascularweb.org/vascularhealth/pages/abdominal-aortic-aneurysm.aspx)

2.4.2

from

AAA pathology
AAA development is associated with the infiltration of inflammatory cells, such as

macrophages and lymphocytes, and is often observed in concurrence with the deposition of
atherosclerotic plaques in the aortic wall [79]. In an attempt to remodel the tissue and eliminate
diseased cells, the inflammatory cells chronically overexpress cytokines that trigger release of
matrix degrading metalloproteases (MMPs). The chronic enzymatic degradation of elastic matrix
in the vessel wall that results due to the overexpression of elastinolytic MMP-2 and -9 by the
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infiltrating inflammatory cells leads to slow AAA growth. Thus, the initial AAA development
stage is characterized by a reduction in the quality and quantity of elastic fibers, accumulation of
proteoglycans, and loss of SMCs [80]. The ECM in and around the AAA site varies due to
numerous parameters including initiating cause, size and location, proximity to site of injury,
stage in development, inflammatory cell involvement and presence of a thrombus [81, 82]. For
instance, the AAA site exhibits significant loss of both elastin and collagen. On the other hand,
sites distal and proximal to it exhibit rapid loss of elastin with minimal net collagen loss, which
can be attributed to the differential hemodynamic load the vessel experiences in these two
regions [83]. Regardless, it is salient to note that disrupted collagen undergoes replacement via
regeneration, which occurs as a compensatory response to increased wall stress perceived by
SMCs upon wall thinning. On the other hand, the elastic matrix does not show such recovery,
due to poor elastogenecity of adult SMCs.

2.4.3

Current strategies for diagnosis and treatment of AAAs
AAAs are typically asymptomatic, rendering their detection difficult. However

recognizing high risk factors for AAAs, pro-active ultrasound screening is now approved for
high risk senior men. Most of such detected AAAs (> 90%) tend to be small (diameter less than
5.5 cm) [84]. The AAAs grow gradually (~10% per year) [85] over five-years or more until they
reach a critical size (> 5.5 cm maximal diameter), at which point they become prone to rupture.
During this period, they are passively monitored via ultrasound. At the critical stage, removal of
the aneurysmal region of the aorta by open surgical means is recommended, or the diseased
segment is replaced with a synthetic vascular graft. Grafts used for AAA repair may be
autologous, allogeneic, xenogeneic, or synthetic, depending on their application. Characteristics
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of an ideal graft include mechanical strength, compliance, kink resistance, non-immunogenicity,
low thrombogenicity, among other properties [86].
Although autologous grafts (e.g., greater saphenous vein or internal mammary artery)
[87] are the most viable clinical option for bypassing of diseased blood vessels, on account of
their lack of immunogenicity, they are often limited by a lack of quality and availability. In the
case of AAAs, these small vessels are also mismatched size-wise with the aorta. Allogeneic
grafts are an attractive substitute due to identical structure, mechanical properties and sizematches and are retrieved from vessels from deceased fetuses, and cadavers [88]. However,
allogeneic tissues may elicit an immune response from the recipient and graft rejection may
occur, which would require lifelong immuno-suppressive therapy to ensure allograft survival
[89].
Xenogeneic (e.g., bovine or porcine) materials, on the other hand, could lead to problems
of end-stage organ failure, and disease transmission [90]. Although xenografts can be processed
(e.g., SDS treatment) to avoid the immune response, this process could compromise the
structural integrity of the resulting acellular matrix composed of elastin and collagen, leading to
compliance mismatch, elastin degradation, inducing thrombogenicity and mechanical stiffening
[90]. Autologous vascular cell seeding of the luminal surface establishing a confluent monolayer
of cells can be used to alleviate the above problems to certain extent [91].
As an alternative to human- or animal-derived grafts, synthetic polymer grafts are usually
used in blood vessel replacement. Most popular kinds of polymeric grafts available are Dacron,
Teflon and polyurethanes [92]. Dacron and Teflon have shown to have greater tensile strengths
and non-biodegradabilty. However, compliance-related issues and formation of neointima
compromise the usability of synthetic grafts [92]. Polyurethane grafts on the other hand, have an
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added advantage of suitable porosity and the ability to regulate compliance. The major
disadvantage of polyurethane grafts is their very slow degradation with time [93].
Open AAA repair is the traditional method for surgical repair/treatment of aneurysms for
the majority of patients. Briefly, this method involves laparotomy and complete removal of the
dilated aorta [8]. This portion is replaced by a Teflon graft which is observed to have a durability
of 20-30 years. However, the mortality rate during the first 30 days can be as high as 4-12% due
to postoperative side effects such as myocardial infarction, renal failure, paraplegia, hepatic
dysfunction and acute respiratory distress syndrome [8, 94].
Considering the risks due to the invasive procedure and high mortality rates, a relatively
less invasive method called endovascular aneurysm repair (EVAR) was introduced in 1990’s. It
involves access to the affected aorta through femoral arteries percutaneously as opposed to large
incisions made in open repair. An endovascular stent graft is inserted and guided to the aneurysm
site using a catheter. The strategically placed stent graft permits blood flow and avoids AAA
growth due to hemodynamic forces on aortic wall in and around the former site of the AAA.
However, limited anatomical (e.g., size, age) suitability, endoleaks due to graft failure/movement
and lifelong surveillance are the disadvantages of EVAR [8]. Currently, unavailability nonsurgical procedure during the 5 year surveillance period for growing aneurysms and population
unable to endure surgeries are major hurdles in longevity of aneurysmal patients.
As elucidated from previous sections, there are currently no pharmacological therapies
available for AAA that can prevent its growth to rupture. These pharmacological therapies can
be a blessing, especially for elderly patients who cannot withstand/survive the surgeries and/or
inefficacies due to complications of surgeries like EVAR. Therefore, based on the inherent
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limitations/disadvantages of surgical and interventional AAA repair, there is a critical need for
designing and developing non-surgical modalities to treat AAAs.

Figure 2.7 Current AAA repair strategies A) open AAA repair; B) Endovascular aneurysmal
repair (Adapted from http://www.vascularweb.org/vascularhealth/pages/abdominal-aorticaneurysm.aspx)

2.5

Elastin restorative strategies
Since elastin degradation is a major determinant of AAA growth, its regeneration is

critical towards the restoration of normal aortic wall architecture in/around the AAA site. This
can then lead to the arrest or stabilization, or even possibly regression of AAA growth, with the
newly synthesized elastic matrix combining with the existing elastic matrix to provide the vessel
wall with the necessary mechanical properties which help maintain vessel structure and integrity,
and also restoring healthy phenotype of the vascular SMCs they would interface with.
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2.5.1

Elastic matrix preservation strategies
As discussed in previous sections, one of the major causes of progressively growing

AAA is disruption of elastic matrix due to the elastolytic activity due to chronically
overexpressed MMPs-2 and -9. Elastin preservative strategies aim to maintain matrix stability by
inhibiting proteolytic enzyme production or attenuating/inhibiting their activity using
pharmacologic MMP inhibitors, and transcription factor regulators, towards outcomes of slowing
matrix degradation, and AAA growth.
Tetracyclines and their derivatives, such as doxycycline (DOX), have been shown to have
broad-spectrum inhibitory effects on MMPs [12], including MMPs-2 [13, 95] and -9 [95]. This
has been attributed to their inhibition of MMP mRNA transcription [12]. Moreover, studies have
demonstrated that DOX treatment inhibits the enzymatic activity of MMP-2 and -9 or pro-MMP
activation in certain cell types (vascular SMCs) [96]. Likely due to its MMP-inhibitory effects,
DOX has appears to delay the progression of AAAs in induced animal models of AAAs [6], as
well as in AAA patients [97], following oral dosing. However, it must also be noted that oral
doses of DOX appear to generate dose-dependent side effects [98], with doses in the µg/mL
range (typically observed in the circulation following oral dosage) likely inhibitory to elastic
matrix synthesis by a variety of cell types [99], including vascular SMCs [100]. Hence, the dose
of DOX and its derivatives should be regulated so as to avoid any interference with elastic matrix
synthesis and deposition by SMCs. MMPs can also be inhibited endogenously by tissue inhibitor
of MMPs (TIMPs); however, the usefulness of TIMPs have been compromised due to issues
with large-scale TIMP production, coupled with undesirable outcomes such as cellular apoptosis,
which certain TIMPs (e.g., TIMP-3) can induce moreover, since TIMPs are vitally important to
regulating various psychological remodeling processes and normal matrix turnover in healthy
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tissues, their delivery must be tightly controlled and localized [14]. Serine proteinase inhibitors,
such as α 1 -antitrypsin, have been shown to prevent unrestricted and potentially harmful effects of
proteases on elastic matrices and protect them from degradation by irreversibly binding to
elastases [101]. Exogenous delivery of alternative elastase inhibitors or transfection of vascular
SMCs with genes (e.g., antitrypsin gene) that help to enhance in vivo production of the elastase
inhibitors resulting in inhibited elastin degradation, is another attractive, potential approach [101,
102].
Transcription factors regulate formation of RNA that codes for assembly of proteins in
the cell cytoplasm. Transcription factors can be selectively activated or deactivated. In the
vascular context, inflammation is specifically regulated by transcription factors that specifically
upregulate MMP synthesis and release [15]. Therefore, inhibition of such transcription factors is
an approach to treat matrix degradation. However, in the context that MMPs are not globally
detrimental in their actions, and indeed serve many useful roles including facilitating normal
tissue/matrix turnover. It is not wise to inhibit transcription factors to totally shut off or attenuate
MMP synthesis.
Despite the promise held by the techniques discussed above, regression of AAAs is not
possible, since elastic matrix is not regenerated actively, a necessary condition for complete
AAA growth arrest. Emerging studies in the field have sought to address this problem by
focusing on strategies to regenerate elastic matrix.
Chemical crosslinking of vascular elastin is a novel and promising approach to preserve
the elastic matrix against enzymatic degradation. Pentagalloyl glucose (PGG), a polyphenolic
tannin produced from tannic acid has been shown to attenuate elastic loss from crosslinked/treated blood vessels and preserve the integrity of the elastic lamellae to reduce aneurysm
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expansion without particularly increasing inflammation, matrix calcification, or influencing
MMP overexpression/activity at the AAA site [103].

2.5.2

Strategies for regenerative elastic matrix repair
Regenerative medicine is defined as “repair, replacement or regeneration of cells, tissue

or organs to restore impaired tissue function resulting from disease, trauma or aging” [104,
105]. Closely associated with regenerative medicine is the field of tissue engineering, which can
manifest itself as in vitro or in vivo applicable technologies, and broadly defined as “combination
of integral knowledge from physicists, chemists, engineers, material scientists, biologists and
physicians to a comprehensive interdisciplinary approach towards development of biological
substitutes” [106]. It is an emerging, and promising alternative to the strategies discussed earlier
with respect to preservation of elastic matrices and replacement. The central theme of tissue
engineering lies in the ability to utilize living cells in a variety of ways using biomaterial,
biomolecule, and mechanical stimuli to repair and/or regenerate tissue. The major goal for
vascular tissue engineering is to restore/replace/augment functional and structurally and
biologically faithful vascular tissue components. Ideally, ‘engineered’ tissues should provide a
microenvironment that replicates that in healthy parenchyma tissue in providing nutrient
transport, provides mechanical and phenotypic stability, and maintaining cell-cell and cell-matrix
interactions.
Matrix engineering is a sub-field within tissue engineering that specifically aims to
restore, maintain, and improve defective, damage, or injured ECM structures, which is crucial to
maintaining tissue homeostasis. The regeneration of elastic matrix in particular, though critical to
vascular homeostasis, has proven to be exceptionally challenging. Due to inherent deficiency of
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adult and vascular cells, more so diseased cells to synthesize elastin precursors and assemble
them into structurally and biologically–faithful mimics of native elastic matrix, as discussed in
section 2.3.2. An even greater challenge lies in overcoming the above deficiencies within a
proteolytic-active/compromised tissue microenvironment that deters new tissue matrix
accumulation and compromises its quality. The following sections provide an overview of
progress made towards overcoming these problems, and continuing challenges.

2.5.3

Elastogenic Induction of SMCs
The presence of GFs in the cellular microenvironment, and their engagement of cellular

membrane receptors trigger the activation or inhibition of intracellular signaling proteins and
pathways. On these lines, various biomolecular cues are responsible for mediating elastic matrix
synthesis. Studies have identified numerous elastin synthesis stimulators (e.g., cGMP [107], fetal
calf serum [108], insulin-like growth factor 1 (IGF-1) [17, 109]) enlisted in Tables 2.1 and 2.2
and elastin synthesis inhibitors (e.g., ascorbic acid [110, 111], cAMP [107], bFGF [112] and
monensin [113, 114]) in Tables 2.2 and 2.3.
Studies have demonstrated the effects of TGF-β1 and IGF-1 in upregulating mRNA
expression of tropoelastin by SMCs, and consequent protein translation and matrix deposition
[115]. Previous studies in our laboratory have shown the elastogenic effects of TGF-β1 and IGF1 when synergistically dosed with hyaluronan oligomers (HA-o – specifically 4-mers and 6mers) on rat and human aortic SMCs [116-118]. The co-delivery of these factors resulted in
increased production of tropoelastin and significant improvement synthesis and alignment of the
elastic fibers into matrix structures.
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Table 2.1

Biomolecular agents stimulating elastin synthesis and matrix deposition [59]

Biomolecule
Cyclic GMP

Retinoic acid

Specific Impacts
↑ Elastin synthesis in presence of
intracellular Ca2+
≥ 5% w/v ↑ elastin synthesis
↑ Tropoelastin and matrix assembly
↑ Tropoelastin synthesis
↑ Tropoelastin synthesis
↑ Tropoelastin synthesis and fiber
formation
↑ Tropoelastin synthesis, ↑ fibrillin

Lysyl oxidase
HA oligomers

↑ Tropoelastin and matrix assembly
↑ Tropoelastin and matrix assembly

HGF

↑ Tropoelastin synthesis

Fetal calf serum
IGF-1
Dexamethasone
Bleomycin
Aldosterone

Cell Type
Ligament fibroblasts

References
[107]

Ligament fibroblasts
Aortic SMCs
Ligament fibroblasts
Ligament fibroblasts
Dermal fibroblasts

[108]
[17, 109]
[108]
[108]
[119]

Vascular
SMCs, [120, 121]
dermal fibroblasts
Aortic SMCs
[122]
Aortic SMCs
[17, 117,
123]
VFFs
[124]

Table 2.2
Biomolecular agents stimulating and also inhibiting elastin synthesis and
deposition [59]
Biomolecule
HA-long chain

TGF-β1

Cu2+ ion

2.6

Specific Impacts
↑
Tropoelastin,
↑
tropoelastin
crosslinking, ↑ versican binding, ↓
elastin fiber assembly
↑ LOX expression and activity, ↓
MMP-2,-9, ↑ TIMP -1,-2,-3, ↑ elastin
synthesis, matrix mineralization at high
doses
↑ Crosslinking, toxic at high doses

Cell Type
Aortic SMCs

References
[117, 118]

Aortic SMCs

[16, 21, 116]

Fibroblast, SMCs, [60]
Aortic SMCs

Elastogenic effects of TGF-β1 in SMC cultures
TGF-β1 is a cytokine which plays a critical role in the cellular expression of elastin and

collagen genes [21]. As elucidated in the previous section, prior studies have demonstrated that
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Table 2.3
Biomolecule
bFGF
cAMP
Versican
Ascorbic acid

Theophylline
Monensin

Biomolecular agents inhibiting elastin synthesis and deposition [59]
Specific Impacts
↓ Tropoelastin synthesis, ↓ elastin
mRNA
↓ Tropoelastin synthesis, cGMP
antagonist
Release of EBP from cell surface
leading to ↓ elastin fiber assembly
↓ LOX activity, ↓ crosslinking of
tropoelastin, ↓ tropoelastin synthesis
and matrix assembly
↓
Tropoelastin
dexamethasone antagonist
↓ Tropoelastin synthesis

Bafilomycin
A1
Chloroquine

↓ Tropoelastin synthesis

NH 4 Cl

↓ Tropoelastin synthesis

Cell Type
Lung fibroblasts

References
[125]

Ligament fibroblasts

[107]

Aortic SMCs

[53]

Aortic SMCs, dermal [110, 111]
fibroblasts,
pulmonary
arterial
SMCs
synthesis, Ligament fibroblasts [108]
Ligament fibroblasts,
aortic
SMCs,
chondrocytes
Ligament fibroblasts,
chondrocytes
Ligament fibroblasts,
chondrocytes
Ligament fibroblasts,
chondrocytes

↓ Tropoelastin synthesis

[113, 114]

[113]
[113]
[113]

TGF-β1 improves matrix assembly by enhancing LOX mRNA expression and its activity [126,
127] and preventing breakdown of existing elastic matrix by downregulating MMP-2 and MMP9 [19, 21]. It has also been shown to play a role in the upregulation of TIMP 1, 2 and 3 [19].
Other groups have illustrated the overexpression of TGF-β1 following endovascular gene
therapy to improved AAA stabilization in experimental animal models, decrease in infiltration of
inflammatory cells, and reduction in MMP-2 and -9 although specific effects on elastin
regeneration were not studied [21].
Studies carried out in our laboratory determined the TGF-β1 dose ranges deemed to have
elastogenic effects on vascular SMCs of rat and human, healthy and aneurysmal. The effective
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TGF-β1 dose promoting elastin synthesis tested and reported was 1.0 ng/mL [16, 116], but could
certainly be higher or lower, due to known biphasic dose effects of TGF-β1 [128]. The studied
doses of TGF-β1 were found to improve both tropoelastin synthesis and also matrix deposition
and fiber assembly by the vascular SMCs [64, 116], which may be attributed at least in part to
the upregulation of elastin at the mRNA and protein levels, as demonstrated by in vitro studies
by other research groups [129]. The predominant effect of TGF-β1 on elastic matrix synthesis
appears to be the stabilization of elastin mRNA [129], which can be attributed to the presence of
a TGF-β1–responsive element in the human elastin promoter [130].
Previous research from the lab suggests that TGF-β1 (1.0 ng/mL, 0.25 fg/cell) inhibits
undesirable hyper-proliferation of SMCs, and also showed that HA-o, when concurrently
provided to cells synergistically enhance the elastogenic effects; tropoelastin synthesis by
healthy rat aortic SMCs was increased ~9-fold relative to untreated control types [16]. These
studies suggest that TGF-β1 facilitates tropoelastin recruitment for crosslinking and matrix
assembly, as demonstrated by increases in the ratios of matrix to total elastin (i.e.; tropo-matrix
elastin). This could be an effect of the observed TGF-β1induced increase in LOX protein
synthesis and activity. TGF-β1 does not appear to enhance the extent of crosslinking itself, since
desmosine amounts on a per cell basis remained unchanged relative to controls.
However, it must be noted that excessive doses (above 10.0 ng/mL dose) leading to
undesirable outcomes/effects, such as matrix mineralization/calcification [16, 20]. Hence, in
order to delivery TGF-β1 doses which stimulate elastogenesis by vascular SMCs, while
concurrently avoiding systemic, undesirable effects, there is a need for a delivery system which
enables its localized, controlled, and sustained delivery.
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2.7

Controlled, localized delivery of therapeutic biomolecules

2.7.1

Nanoparticles as delivery vehicles
As discussed in the previous section, controlled delivery of GFs is essential to enable

sustained therapeutic effect, and to reduce adverse side-effects of their systemic-, or overavailability. An overview of advantages of bio-degradable PLGA NPs has been illustrated in
Table 2.4. This has been accomplished successfully with many therapeutic agents via delivery
from polymeric nanoparticles, which serve as vehicular reservoirs for GFs and enable their
localized, controlled and sustained delivery at the desired tissue site.
Table 2.4 An overview of advantages of bio-degradable PLGA NPs
Properties
Usability
Stability
Size
Site specific
delivery
SA/V ratio
Release
characteristics

Advantages
Ability to encapsulate macrocmolecules, nucleic acids,
proteins, growth factors, peptides and hormones
Stability of drug (structure and function) during storage
Cellular uptake and intracellular trafficking, do not induce
inflammatory response by host
Catheter based approach; cellular and tissue targeted
delivery: oral, intravascular delivery possible
Enable larger surface area for buffer penetration and result
in higher drug release
Long term release profiles, non-repeated drug
administration

References
[131-133]
[134]
[135]
[132, 135]
[136]
[131]

GFs may be encapsulated or tethered to the NP surface [137], with the former approach
being preferred on account of it enhancing the half-life of the GFs, and thereby enabling their
enhanced therapeutic effect(s) [137]. A variety of nanoparticle properties play a critical role in
mediating the functional effects of these GFs following their delivery.
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2.7.2

Nanoparticle characteristics and implications to drug delivery
Nanotechnology, as an emerging field in human medicine, has a wider extent of

applications due to its hetero-functionality. There have been many studies with different types of
NPs obtained from variety materials, as illustrated in Table 2.5. Nanoparticle size is a critical
parameter, which mediates their uptake/localization within targeted cells and tissues [137, 138]
following their delivery. For example, diseased tissue microenvironments are often characterized
by increased permeability due to enhanced vascularity or matrix disruption [139], which
improves permeation of these nanoparticles into/at the desired site. Studies have demonstrated
that particles larger than 500 nm resulted in events such as phagocytic attack while NP sizes
smaller than 100 nm have been shown to elicit immunogenic response [138]. Nanoparticles can
be surface functionalized with various chemical groups to modulate their charge, improve
binding affinity to specific cellular domains and enhance their intracellular uptake. For example,
the cationic functionalization of nanoparticles has been shown to enhance their uptake in the
aortic wall [135], as well as intracellular uptake by SMCs, which then has the potential to
enhance and sustain their therapeutic effect(s).
The large surface area-to-volume ratio exhibited by NPs enable sustained high rate of
release of encapsulated agent(s). The diffusion characteristics and degradation profiles of
nanoparticles have been studied widely, which allow us to design them such as to ensure the long
term delivery of GFs in controllable pattern into/at targeted sites. For example, higher percentage
of glycolic acid in composition of PLGA results in accelerated weight loss of polymer and hence
a faster release of the active agent, for example a 50:50 PLGA molecule degrades faster
compared to 65:35 PLGA molecule. [136, 140]. In case of molecular weights, a PLGA polymer
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with higher molecular weight tends to degrade slowly because of its ability to form long
polymeric chains [136, 141].
Table 2.5 Different types of NP matrices and their applications [142]
Material Class
Natural materials or
derivatives
Dendrimers
Fullerenes

Polymer carriers

Ferrofluids

2.7.3

Materials
Chitosan,Dextrane, Gelatine,
Alginates, Liposomes, Starch
Branched polymers
Carbon based carriers
Polylacticacid,
Poly(cyano)acrylates,
Polyethyleinemine
Blockcopolymers
Polycaprolactone
SPIONS
USPIONS

Application
Drug/Gene delivery
Drug delivery
Photodynamics, Drug delivery

Drug/gene delivery

Imaging (MRI)

Quantum Dots

Cd/Zn-selenides

Imaging
In vitro diagnostics

Various

Silica-nanoparticles, mixtures
of above

Gene delivery

PLGA as NP matrices
The use of biodegradable polymeric materials in NP based drug delivery systems,

particularly provide an advantage serving the desired purpose, without requiring their surgical
removal from the body post-drug delivery [131]. Poly(lactide-co-glycolide) (PLGA) is one such
biodegradable polymer widely used in field of drug delivery and approved by FDA for clinical
use [143]. It is copolymer of poly-lactic acid (PLA) and poly-glycolic acid (PGA) and is
synthesized by ring opening copolymerization of cyclic dimers within the monomers [131].
PLGA is an apt polymer for implantation because of its biocompatibility owing to its
hydrolytic breakdown/biodegradation into lactic and glycolic acid, both of which are non-toxic
to the human body, as they are the natural byproducts of metabolic pathways in vivo. The
variation of the lactide:glycolide ratio and its molecular weight, provide a wide range of
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degradation profiles for PLGA [131, 136], with the surrounding pH and temperature also playing
important roles [131, 136]. The degradation primarily occurs in multiple steps via bulk diffusion,
surface diffusion, bulk erosion and surface erosion processes [136]. This is illustrated by the fact
that PLGA nanoparticles loaded with therapeutics exhibit a biphasic release pattern [136]. The
release is initialized by the diffusion of water into the polymer matrix, which leads to the
diffusion of therapeutic agent, enabling its release, as well as the hydrolysis of ester bonds within
the polymer matrix which leads to the degradation of the polymer [131, 136].

2.7.4

Controlled delivery of TGF-β1
There is only one published study reported on delivery of TGF-β1 from PLGA

microspheres towards achieving controlled bone regeneration [144]. However, NPs have
advantages over microspheres wherein microspheres tend to form fibrotic capsules due to
inflammatory response. Most importantly, microspheres are associated with poor cellular uptake
and intracellular trafficking when compared to NPs [132]. In the present study, based on our
observed in vitro elastogenic effects of TGF-β1 [16, 116], we sought to develop PLGA NPs for
(a) enhancing arterial uptake and retention in the aortic wall, (b) enabling controlled, long-term
release of TGF-β1, towards (c) promoting elastin regeneration and/or matrix assembly at AAA
sites. More specifically, we determined the in vitro release profile of TGF-β1 from the PLGA
nanoparticles as a function of TGF-β1 loading, b) analyzed its bioavailability and bioactivity and
finally c) evaluated its impact on elastin regeneration and elastic matrix formation by aneurysmal
rat aortic SMCs. Additionally, the nanoparticles were functionalized with poly-vinyl alcohol
(PVA) [145] as a non-ionic stabilizer for the nanoparticle system, which provided the NPs with
uniform size distribution [133, 145] and imparts an overall negative charge on nanoparticles
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[146]. At the same time, there is also significant potential for surface modification of NPs using
cationic amphiphiles such as didodecyldimethyl ammonium bromide (DMAB). The use of these
cationic amphiphiles have been demonstrated to not only impart the NPs with a positive surface
charge, and enhance their arterial uptake and retention, but also enable their binding with high
affinity towards elastin [147, 148] and enhancing elastin fiber crosslinking via upregulation of
LOX activity.
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CHAPTER III
MATERIALS AND METHODS

3.1

Development and characterization of TGF-β1 loaded nanoparticles

3.1.1

Reconstitution of TGF-β1
The recombinant human TGF-β1 (Catalog no. 240-B; R&D Systems, Minneapolis, MN)

was purchased for the purpose of encapsulation within PLGA nanoparticles. The lyophilized
TGF-β1 was activated and reconstituted in acidic buffer as directed by the company and stored at
-80°C for long term storage. Briefly, lyophilized TGF-β1 was activated by 100 µL of sterile
4mM hydrochloric acid (HCl) containing 0.1% w/v bovine serum albumin (BSA; Catalog no.
0332; Amresco, Inc. Solon, OH). This resultant 100 µg/mL solution was split into five aliquots
of 20 µL containing 2µg each and stored into -80°C. Prior to the use of TGF-β1, the aliquot was
thawed out in ice. The required volume was made up in phosphate buffer saline (PBS; Catalog
no. P3813; pH 7.4; Sigma-Aldrich, St. Louis, MO) supplemented with 0.1% w/v BSA.
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3.1.2

Formulation of nanoparticles
The formulation of NPs was carried out in two ways; one method included surface

functionalization of NPs with PVA (Sigma-Aldrich), which also served as a stabilizer, while the
other method involved surface functionalization with DMAB (Sigma-Aldrich). Briefly, poly (dllactic-co-glycolic acid) NPs (PLGA; 50:50 lactide: glycolide; inherent viscosity of 0.95-1.20
dL/g in hexafluoroisopropanol (HFIP); Durect Corporation, Birmingham, AL) were loaded with
TGF-β1 (R&D Systems, Inc). The NPs were prepared by a double-emulsion/solvent-evaporation
technique [131, 136] for both formulations. In case of the PVA-functionalized NPs, 2.5-3.0%
w/v PLGA was dissolved in 2 ml of dichloromethane (DCM). As described in the previous
section, aliquots containing 1 µg, 2 µg and 5 µg were dissolved in PBS with 0.1% w/v BSA to
prepare a total of 100 µL aqueous TGF-β1 solution, in each case, which were co-encapsulated
with an equal volume of 10% w/v BSA solution [149]. These aqueous TGF-β1 solutions were
emulsified into PLGA solution using a probe sonicator (Q500; QSonica LLC, Newtown, CT) for
1 minute on ice at 20% set amplitude. The water-in-oil emulsion thus formed was further
emulsified into an aqueous 0.25% w/v PVA solution using a probe sonicator for 1 minute on ice
at 20% set amplitude to form a water-in-oil-in-water emulsion. The second emulsion was stirred
using magnetic stirrer for 16 h at room temperature followed by desiccation for 1 h under
vacuum to remove any residual DCM. The NPs thus formed were recovered via 3 washing
cycles by ultracentrifugation (Beckman Instruments, Inc., Palo Alto, CA) at 35,000 rpm for 30
min at 4°C. The NPs were lyophilized over 48 h to obtain a dry powder. The supernatants
obtained during the washing cycles contained residual PVA and unencapsulated TGF-β1 and
were assessed to determine encapsulation efficiency.
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NPs prepared with DMAB as stabilizer, were expected to incorporate the surfactant
molecules on NP surfaces, and to carry an overall positive surface charge which could enhance
the ability of NPs for arterial uptake as described in Section 2.7.4. Briefly, 2.5-3.0% w/v 50:50
PLGA was dissolved in 2 mL of chloroform. TGF-β1 (100, 200 and 300 ng) aliquots were
dissolved in PBS containing 0.1% w/v BSA, to make a total of 100 µl in each case. This aqueous
TGF-β1 was emulsified into the PLGA solution using a probe sonicator for 1 minute on ice at
20% set amplitude to obtain a first water-in-oil emulsion. This was further emulsified into an
aqueous 1.0 % w/v DMAB solution using a probe sonicator for 1 minute on ice at 20% set
amplitude to form a water-in-oil-in-water (w-o-w) emulsion. The procedure following the
formation of w-o-w emulsion is similar to the procedure mentioned previously, in case of PVAfunctionalized NPs. The supernatants obtained during the washing cycles contained residual
DMAB and unencapsulated TGF-β1 and were collected for the purpose of evaluating
encapsulation efficiency.
However, as will be discussed in detail in Chapter 4, our experiments showed TGF-β1loaded NPs functionalized with DMAB, to interfere with detectability of TGF-β1 via ELISA
thus preventing reliable estimation of its release, centric to the goals of this project. Accordingly,
the 2 µg TGF-β1-loaded, PVA-functionalized formulation was set as solely studied further in
cell culture experiments.

3.1.3

Efficiency of encapsulation of TGF-β in nanoparticles
The supernatant solutions obtained during the wash cycles of nanoparticulate synthesis

process would be expected to contain un-encapsulated TGF-β1. Therefore, the supernatants were
collected and pooled for evaluation of encapsulation efficiency. The amount of un-encapsulated
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TGF-β1 in the supernatants were quantified using a TGF-β1 Quantikine® enzyme-linked
immunosorbent assay (ELISA) kit (Catalog no. DB100B; R&D Systems, Inc). The detected
amount of TGF-β1 in supernatants was subtracted from the total amount of TGF-β1 added
during the encapsulation process, to determine the actual amount of TGF-β1 encapsulated within
the nanoparticles.

3.1.4

Size and surface charge of TGF-β1 nanoparticles
The measurement of size and surface charge on TGF-β1 loaded NPs was carried out

using a commercial particle sizing system (PSS/NICOMP 380/ZLS, Particle Sizing Systems,
Santa Barbara, CA). The size of NPs was determined by measuring the mean hydrodynamic
diameter using dynamic light scattering technique (DLS), and the measurements of surface
charge were determined via phase analysis light scattering system.

3.1.5

In vitro characterization of release of TGF-β1 from nanoparticles
The in vitro release of TGF-β1 from NPs was carried out in PBS containing 0.1% w/v

BSA over the period of 21 days at 37°C on shaker at 100 rpm. Briefly, 10 mg TGF-β1-loaded,
PVA-functionalized NPs by weight were resuspended in 1 mL release media (PBS with 0.1%
BSA) in 1.5 mL polypropylene tubes (n=3) and were placed on a shaker in a 37°C incubator. The
tubes were centrifuged (7,000 rpm, 15 min, 4°C) at specific time points (i.e. 4h, 12h, 1d, 2d, 4d,
7d, 10d, 15d, and 21d). The entire volume was collected at each time point and the tube was
replenished with equal amount of fresh release media. The release samples thus collected were
stored at -20°C until further analysis. The released TGF-β1 was quantified using TGF-β1
Quantikine® ELISA kit.
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The TGF-β1-loaded, DMAB-functionalized NPs were resuspended in PBS with 0.1%
w/v BSA over period of 21 days at 37 °C on shaker at 100 rpm. The procedure for obtaining and
storing release samples was similar to PVA-functionalized NPs.

3.2

Determination of TGF-β1 integrity in release media
The structural integrity/bioavailability of TGF-β1 released from NPs was confirmed by

co-localization of bands corresponding to released TGF-β1 with those corresponding to
exogenous TGF-β1 standards in western blots [149]. As described in section 3.1.5, a suspension
containing 10 mg/mL of NPs loaded with TGF-β1 and 0.1% w/v BSA in PBS, was placed on a
shaker at 37°C for 24 h. The released TGF-β1was recovered by centrifugation and was
concentrated approximately 20-fold through a 10kDa cut-off centrifugal filter (Amicon® Ultra,
Millipore, Inc., Billerica, MA). This protein solution was loaded on a NuPage® 4-12% Bis-Tris
Gel (Invitrogen, Inc., Carlsbad, CA; NP0332) under non-reducing conditions, in parallel with a
SeeBlue® Protein Ladder (Invitrogen, Inc.; LC5925) and TGF-β1 standards. The proteins on the
gel were transferred to a nitrocellulose membrane using the iBlot® gel transfer device
(Invitrogen, Inc.; IB1001). The membrane was blocked for 1 h using blocking buffer (Li-Cor
Biosciences, Lincoln, NE; 927-40000). After blocking, the membrane was immuno-labeled with
anti-human TGF-β1 antibody (Peprotech, Inc., Rocky Hill, NJ; 500-M66) at a dilution of 1:250
v/v in blocking buffer and was placed on shaker for 16 h at 4°C. Finally, the membrane was
washed three times in PBST (phosphate buffer saline with 0.01% v/v Tween 20, pH 7.4) and was
labeled with IRDye® goat polyclonal anti-mouse antibody (Li-Cor Biosciences; 827-08364) at a
dilution of 1:20,000 v/v in blocking buffer containing 1:1000 v/v of 10% w/v SDS solution and
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Tween-20 each, for 1 h. The protein bands were visualized in an Odyssey imager. The
membranes were preserved at 4°C and in dark.

3.3

Determination of functionality of released TGF-β1
TGF-β1 is known and has been demonstrated to inhibit the proliferation of mink lung

epithelial cells (MLCs) at specific doses. Studies have shown that a 100 pico-molar
concentration of TGF-β1, which is equivalent to 2.5-3.0 ng/mL TGF-β1,significantly inhibits the
proliferative nature of MLCs in 2D culture system [150]. Thus, to confirm the bioactivity of the
NP-released TGF-β1, we sought to demonstrate its ability to inhibit MLC proliferation. The
MLCs were purchased from American Type Culture Collection (ATCC, Manassas, VA) and
were expanded in Eagle’s minimum essential medium (EMEM) supplemented with 10% v/v
FBS and 1% v/v Penstrep, cryopreserved according to the literature provided by the company,
and thawed for use in experiments.
MLCs were seeded at a density of 12 × 104 cells per well in 6-well plates (A = 10
cm2/well; BD-Biosciences, Franklin Lakes, NJ), (n = 6 for each treatment condition, for each
time point). The bioactivity of TGF-β1 released from PLGA NPs was compared to non-growthfactor added controls, exogenous added TGF-β1 and blank NPs. Exogenous TGF-β1 was
provided to cells at two different doses, one corresponding to the 3.0 ng/mL ‘inhibitory’
concentration reported previously, and one corresponding to a concentration of 0.03 ng/mL,
previously shown to have no such inhibitory effect on MLCs. Test and control cell cultures were
harvested in Pi buffer (50mM disodium hydrogen phosphate, 2mM EDTA, 0.2% w/v sodium
azide) at 1d, 4d and 7d (1 plate/condition/time point). Medium was not changed during the
culture period. The harvested cell layer was sonicated and stored at -20°C until further assayed.
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A fluorometric DNA assay, described in detail further in Section 3.5.1, was performed on these
harvested cell layers to quantify the cell count at the end of each time point for each treatment
condition and confirm the bioactivity of released TGF-β1.

3.4

Cell Culture

3.4.1

Cell isolation methods
Aneurysmal rat aortic SMCs (EaRASMCs) were isolated from adult male Sprague-

Dawley rats (n =3) at 14-days after inducing an AAA via elastase infusion [151]. Our lab has
adapted this method for isolating cells [64] and the isolation was carried out by my colleagues
Mr. Dennis Wilk and Mr. Partha Deb. To isolate the cells the AAAs were cut open longitudinally
and a scalpel was used to scrape off the intimal layer. The exposed medial layer was sectioned
out from the underlying adventitial layer, chopped into ~0.5 mm long slices, and washed with
warm, sterile PBS. These slices were pooled and enzymatically digested in Dulbecco’s minimum
essential medium-F12 (DMEM-F12; Invitrogen, Grand Island, NY) cell culture medium
containing 125 U/mg collagenase (Worthington Biochemicals, Lakewood, NJ) and 3 U/mg
elastase (Worthington Biochemicals) for 30 min at 37 °C, centrifuged (400 g, 5 min), and
cultured over 2 weeks in T-75 flasks. The cells were cultured in DMEM-F12 medium
supplemented with 10% v/v fetal bovine serum (FBS; PAA Laboratories, Etobicoke, Ontario)
and 1% v/v PenStrep (Thermo Fisher, South Logan, UT). The primary EaRASMCs obtained
from these tissue explants were propagated over 2 weeks, and passaged when they attained
confluence.
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3.4.2

Determining in vitro cytotoxicity of TGF-β1 loaded nanoparticles
The cell cytotoxicity assay was performed on aneurysmal rat aortic smooth muscle cells

(EaRASMCs) to determine the maximum non-cytotoxic nanoparticle dose that could potentially
be used in 2-D cell culture studies.
The cytotoxic effects of NP addition and NP dose were tested in EaRASMC cultures
using a LIVE/DEAD® cell viability assay (Invitrogen). Sterile, 2-well Permanox® chamber slides
(Nalge Nunc International, Rochester, NY) were seeded with 5 × 103 cells per well. The cells
were allowed to adhere for 48 h when cultured with DMEM F-12 cell culture medium
supplemented with 5% v/v FBS and 1% v/v Penstrep. The TGF-β1-loaded NPs were added at
concentrations of 0.1, 0.2, 0.5 and 1 mg/mL and incubated with the cells for 48 h. For the
LIVE/DEAD® assay, the cell layers were washed by sterile PBS after complete aspiration of
medium. The stain solution containing 1 µL/mL calcein AM and 2 µL/mL Ethidium
homodimer-1 in PBS was added to each well and incubated for 45 min at room temperature. The
cell layers were washed three times, again, by PBS and visualized at 20× magnification using an
Olympus IX51 fluorescence microscope (Olympus America, Center Valley, PA).The viable cells
were visualized as green and dead cells as red.

3.4.3

Experimental design for culture studies for matrix assessment
EaRASMCs were expanded in T-75 flasks at passage 1, in DMEM-F12 medium

containing 5% v/v FBS and 1% v/v PenStrep (culture medium). These EaRASMCs were
trypsinized and seeded at 6 × 104 cells per well in 6-well plates (A = 10 cm2), for matrix assays,
PCR and western blot analyses; and 5 × 103 cells per well for immuno-fluorescence studies in 240

well Permanox® chamber slides(A = 2 cm2)(Nalge Nunc International). The cells were allowed
to adhere to wells over 48 h. Cell layers from one 6-well plate, designated as 0-day cultures’,
were harvested in Pi buffer to quantify initial seeded cell counts, and other cell layers were
further cultured under respective treatment conditions. The effects of released TGF-β1 on
EaRASMCs were ascertained by comparing cell cultures 0.5 mg/mL TGF-β1 NPs with cultures
containing (a) No NPs - culture medium only, (b) exogenous TGF-β1 equivalent to ~1ng/mL
over the total cell culture period of 21 days and (c) blank NPs at the concentration of 0.5 mg/mL.
Briefly, the volume of medium used for each test culture was 5 mL per well and the spent
medium was replaced every 7 days. The culture medium was aspirated out and replenished with
fresh culture medium for the non-additive treatment condition. The exogenously added TGF-β1
was to be supplemented for 7 days until media change, therefore 1.75 ng TGF-β1 was added to 5
mL culture medium to fulfill the requirement of 1 ng/mL over 21-day period and replenished as
described earlier. In case of TGF-β1 loaded- and blank NPs, entire 5 ml of existing 0.5 mg/ml
NP-containing, spent culture medium, from each well, was pipetted out and split into five 1.5
mL-eppendorf tubes. These tubes were then centrifuged at 7000 rpm for 15 min at 4°C to recover
NPs from the spent medium. The supernatants were aspirated out leaving behind NP pellets,
which were each replenished by addition of 1 ml of fresh culture medium. The medium aliquots
from the five tubes corresponding to each well were pooled, and pipetted into the respective
wells.
At the end of 7 days, the cells were harvested for PCR analysis using RLT buffer
(Qiagen, Valencia, CA); which is a cell and tissue lysis buffer. The lysed cell layers were
resuspended in 350 µL of RLT buffer and stored at -80 °C until RNA isolation and processing
samples for PCR.
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At the end of 21 days, the cells were harvested for further analysis. The cells used for the
estimation of cell proliferation and other matrix assays (elastin and collagen quantification) were
harvested in Pi buffer. The culture medium was completely aspirated out and the wells were
rinsed three times with sterile PBS to remove any DNases. The wells were then each filled with 1
mL of Pi buffer and scraped using scraper to detach the adhered cells and matrix to ensure
complete recovery. This process was repeated two times and therefore a total of 3 ml containing
cell layer was pooled and split into three 1.5 mL-eppendorf tubes. These tubes were stored at 20°C until further analysis.
Finally, the cell layers to be assessed via western blot analysis were harvested in RIPA
buffer (Invitrogen, Inc), containing 1% protease inhibitor (Thermo Scientific, Rockford,
IL).Briefly, the culture medium was completely aspirated and 500 µL of RIPA buffer was added
to each well. It is important to note that the cell layers were scraped on ice, collected into 1.5
mL-eppendorf tubes and stored in -20°C until further analysis. Prior to their storage, a BCA
assay (Thermo Scientific, Inc) was performed on harvested samples to estimate the protein
content. Based on the results from BCA assay, single-use aliquots (~50 µL) were made and
stored at -20°C.

3.5

Matrix Assays

3.5.1

DNA Assay
The effect of TGF-β1 loaded NPs on proliferation of EaRASMCs was determined by

measuring the total DNA content in the cell layers and its comparison with the control cases, via
a fluorometric assay as described by Labarca and Paigen [152]. Briefly, the cell layers were
harvested at 1d time point and 21d time point of culture period, in Pi buffer. The harvested cell
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layers were sonicated on ice for a total of 30 sec, with alternating 5 sec pulse and 5 sec pause.
DNA standards used were the serial dilutions from 10 µg/mL stock solution of calf thymus
DNA. Briefly, 100 µL of sample was diluted in 395 µL of Pi buffer and mixed with 505 µL of 2
µg/mL Pentahydrate (bis-benzimide) (Hoechst 33258; Invitrogen, Inc) solution in Pi buffer. The
sample and standard tubes were vortexed well and incubated at room temperature in dark for 30
min. A 200 µL aliquot was pipetted out in each well of 96-well, fluorescence plate, and read at
excitation set to λ = 356 nm and emission set to λ = 458 nm. The cell layers were thus assayed
for DNA content and the cell density was therefore calculated assuming 6 pg of DNA/cell [152].

3.5.2

Fastin Assay
The total elastin content in the cell layer (alkali-soluble and insoluble matrix fractions)

was quantified using a Fastin elastin assay kit (Biocolor, Inc, UK). The cell layers were
harvested after 21 days of culture and resuspended in Pi buffer. These cell layer fractions were
then sonicated on ice for 30 sec in all, alternating 5 sec pulse and 5 sec pause, to homogenize the
cell layer. The resultant suspension was centrifuged at 2500 rpm for 10 min and Pi buffer was
subsequently aspirated. The pellet was suspended in 1 mL of 0.1N NaOH and digested for 1 h at
98ºC. The suspension was centrifuged at 10,000 rpm for 10 min, and supernatant containing
alkali-soluble elastin was recovered ensuring that the pellet remained undisturbed. The pellet was
then suspended into 1 mL 0.25M oxalic acid and digested at 95°C for 1 h, to convert the
insoluble fraction of elastin into soluble, α-elastin detected by Fastin assay kit. The resultant
suspension was passed through 10-kDa cut off centrifugal filters (Amicon® Ultra, Millipore, Inc.,
Billerica, MA) and the retentate (containing alkali-insoluble elastin) was collected by reverse
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centrifugation, and labeled as insoluble elastin. The digested elastin samples, soluble and
insoluble fractions, were stored at 4°C.
The sample volume used to perform the Fastin assay was 100 µL from the elastin
samples isolated previously. It is important to note that the volumes at the end of filter
centrifugation were not equal. Therefore, the volume in all the tubes were made up to 100 µL.
Briefly, 100 µL of samples for all the test conditions was mixed with 100 µL of elastin
precipitating reagent in a 1.5 mL-eppendorf tube. The suspension was vortexed and incubated for
15 min at room temperature. The tubes were then centrifuged at 14,000 rpm for 20 min in a
microcentrifuge. The content of the tubes was then decanted into a glass beaker and the tubes
tapped on a paper towel to ensure maximum decantation. The upper sides of the tubes were
cleaned with a Q-tip and it was ensured that the contents would be less than 25 µL. Later, 500
µL of the elastin dye was added to the tubes and incubated for 90 min at room temperature. At
the end of this incubation period, the tubes were again centrifuged at 14,000 rpm for 20 min. The
contents in the tube were dried out by decantation procedure mentioned above. A reddish-brown
colored pellet, visible at the bottom of the tubes, was dye bound elastin. The tubes were then
filled with 250 µL of dye dissociation agent, and vortexed well. The entire 250 µL volume was
pipetted out and read in a clear, absorbance 96-well plate via spectrophotometer (SpectraMax
M2, Molecular Devices, Inc., Sunnyvale, CA) at λ = 513 nm. Note that the sample absorbances
were read in triplicate, used to estimate elastin amounts per well, and then normalized to
corresponding cell counts from DNA assay to provide accurate comparison between treatment
conditions.
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3.5.3

Hydroxy-Proline Assay
A hydroxyl-proline (OH-Pro) assay was used to estimate the collagen content within test

and control cell layers. On the grounds of presence of 4% w/w OH-Pro in soluble elastin, 500 µL
of soluble elastin isolated, as described in previous section, was further digested to obtain OHPro residues. The solubilized elastin in 0.1N NaOH was neutralized by adding 500 µL of 6N
hydrochloric acid (HCl) in 2 mL glass vials. The tubes were tightly capped and placed in a
heating block for 16 h set at 110°C. The lids of the tubes were then removed and dried with
nitrogen gas treatment for approximately 90 min, leaving a white precipitated residue at the
bottom of vials. These vials were then reconstituted with 100 µL of de-ionized water and stored
at 4°C until assay.
The standards were prepared as a serial dilution of 6 µg of OH-Pro from a 1 mg/mL OHPro stock solution. Briefly, 20 µL of the OH-Pro isolated samples from cell layers and standard
samples were added to glass tubes containing 500 µL deionized water. Chloramine-T reagent
was prepared by adding 0.353 g of Chloramine T in 20 mL of 50% v/v n-propyl alcohol, and
made up to 100 mL using OH-Pro buffer (50 mg citric acid, 12 mL glacial acetic acid, 120 g
sodium acetate hydrate, 24 g sodium hydroxide, 300 mL n-propyl alcohol, made up to 1.5 L, pH
6.0). Chloramine T reagent (250 µL) was added to the tubes, vortexed and incubated at room
temperature for 15 min. Thereafter, 250 µL of Ehrlich’s reagent (2.25 g p-dimethyl-aminobenzaldehyde, 9 ml n-propyl alcohol, 3.9 ml of 70% perchloric acid) was carefully added to the
suspension in tubes and vortexed, in a chemical hood and placed into a heating block for 15 min
at 60°C. The samples with higher collagen content would appear to turn yellow to red. A 250 µL
aliquot of these solutions was pipetted onto a clear 96-well plate and read for absorbance at λ =
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558 nm [153]. The total collagen content was then calculated on the basis of the 13.2% OH-Pro
content of collagen [154], and normalized to the DNA content of corresponding cell layers.

3.6

Immunofluorescence detection of elastic matrix assembly proteins
Immunofluorescence labeling studies were carried out to visualize the deposition of

elastin, fibrillin and LOX by EaRASMCs in matrix through the culture period, and support other
quantitative assay results. As described previously, 8 × 103 EaRASMCs were seeded in sterile, 2well Permanox® chamber slides (Nalge Nunc International) and treated with respective test
conditions for 21 days, for immunofluorescence studies.
After 21 days of culture, the cell layers were fixed with 4% w/v paraformaldehyde and
blocked using blocking buffer (5% goat serum in PBS) for 1 h. These slides were then treated
with rabbit polyclonal antibodies against elastin (Catalog no. ab21610; Abcam, Cambridge,
MA), fibrillin-1(Catalog no. ab53076; Abcam) and LOX (Catalog no. ab31238; Abcam), all at
1:100 v/v dilutions overnight at 4°C. The slides were washed with PBS and treated with 1:1000
v/v dilution of Alexa Fluor® 633-conjugated goat anti-rabbit secondary antibody (Invitrogen,
Inc.; A-21070). The cell nuclei were stained using a fluorescent nuclear stain 4, 6-diamino-2phenylindole dihydrochloride (DAPI) contained in the mounting medium (Vectashield; Vector
Labs, Burlingame, CA).

3.7

Western Blot for LOX
Western blot analysis was performed to semi-quantitatively assess effects of NPs with

and without TGF-β1, on LOX protein synthesis in EaRASMC cultures. The cell layers from the
test conditions described in Section 3.4.3, were harvested in RIPA buffer. Based on the results
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from BCA assay, an equivalent of 4µg of protein was loaded in 4-12% Bis-Tris Gel (Invitrogen,
Inc.). The proteins were transferred to nitrocellulose membrane using iBlot system (Invitrogen,
Inc.). The membrane was then blocked with blocking buffer (Li-Cor Biosciences) for 1 h, at
room temperature. The membrane was then treated with primary antibodies (1:200 v/v anti-LOX
(SantaCruz Biotechnology, Inc Santa Cruz, CA; SC32410), 1:1000 v/v anti-actin (Sigma
Aldrich; A3853), 1:1000 v/v Tween 20) in blocking buffer for 16 h at 4°C. The membranes were
washed in PBST thrice before treating it with secondary antibody (1:15,000 v/v IRDye® donkey
polyclonal anti-goat (Li-Cor Biosciences), 1:20,000 v/v IRDye® goat polyclonal anti-mouse (LiCor Biosciences), 1:1000 v/v 10% SDS solution, 1:1000 v/v Tween 20) in blocking buffer for 1
h, at room temperature. Finally, the membranes were washed three times in PBST and visualized
under Odyssey Imager.

3.8

Real Time Polymerase Chain Reaction (RT-PCR) for quantifying mRNA expression

of proteins associated with elastin synthesis processes
3.8.1

Isolation of mRNA
The cell layer suspension was diluted with 350 µL of 70% v/v ethanol. The resultant 700

µL of cell layer suspension was transferred to RNeasy spin column and centrifuged for 30 sec.
The flow-through was discarded from the collecting tube and 700 µL RW1 was added to the spin
column. This suspension was centrifuged for 15 sec at 10000 rpm. The flow-through was
discarded again discarded and 500 µL of 1× RPE buffer was added to the spin column. This was
centrifuged for 15 sec at 10000 rpm and 500 µL of 1× RPE buffer was again added to the spin
column. The 15 sec centrifugation at 10000 rpm was repeated and the flow-through was
discarded. The spin column was transferred to another collecting tube. The spin column was
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centrifuged for 1 min at 14000 rpm. Later, the spin column was again transferred to a 1.5 mL
collecting tube and 30 µL of DEPC water was added to spin column. This was centrifuged at
14000 rpm for 1 min. The filtrate (~30 µL) was added back to spin column to ensure complete
mRNA recovery and centrifuged at 14000 rpm for 1 min. The filtrate was stored at -80 °C.

3.8.2

mRNA quantification
The mRNA was quantified using the Ribo-green assay kit (Invitrogen). Briefly, 2 µL of

isolated mRNA was diluted with Tris-EDTA (TE) buffer to make a 100 µL of total assay sample,
and pipetted into an opaque, fluorescence 96-well plate. A 100 µL aliquot of working ribo-green
reagent (diluted in TE buffer) was added to each assay sample in the 96-well plate. The samples
were quantified using a standard curve obtained from the serial dilutions of 2 µg/mL of mRNA
standards, which were supplied with the kit. The fluorescence of samples was read at excitation
of λ = 480 nm and emission of λ = 520 nm.

3.8.3

Reverse transcription of mRNA
The reverse transcription of mRNA results in cDNA that serves as template in

amplification process of RT-PCR. Approximately 400 ng of mRNA, mixed with recommended
concentrations of reverse transciptase (RTase) and reaction buffer cocktail, was reverse
transcribed using iScript cDNA synthesis kit (Biorad Inc, Hercules, CA). The reaction mixture
was placed in a thermocycler and converted to cDNAs.
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3.8.4

RT-PCR
RT-PCR was used to evaluate the gene expression of proteins of interest, associated with

elastin assembly process, in cultures treated with TGF-β1 NPs and compared to untreated
cultures. Specifically, this study aimed to focus on the gene expression of elastin, collagen type1, LOX, fibrillin-1 and fibulin-5. The elastin (Eln) [16], collagen (Col1a1) [155] and fibrillin-1
(Fbn1) primers used for amplifying the cDNAs in the RT-PCR, and were designed by senior
colleague in our lab, Dr. Chris Bashur, while the 18S (house-keeping gene; Rn18s), fibulin-5
(Fbln5) and LOX (Lox) primers were commercially purchased from Real Time Primers, LLC
(Elkins Park, PA).
Table 3.1 Proteins associated with elastin synthesis and their primer sequences
Protein

Forward primer sequence
5’ - 3’

Reverse primer sequence
5’ - 3’

Size
(bp)

Eln
Col1a1
Fbn1
Fbln5
Lox

CCTGGTGGTGTTACTGGTATTGG
GAGGGCGAGTGCTGTCCTT
ATAAATGAATGTGCCCAGAATCCC
CGAGGGTCGAGAGTTCTACA
AGACGATTTGCCTGTACTGC

CCGCCTTAGCAGCAGATTTGG
GGTCCCTCGACTCCTATGACTTC
ACTCATCCTCATCTTTACACATCC
CAGAACGGATACTGGGACAC
ATAGGCGTGATGTCCTGTGT

60
74
132
186
219

Briefly, 2 µL of cDNA, which is equivalent to 8 ng cDNA, was mixed in appropriate
concentrations of primers and 10 µL of Power-SYBR® Green Master Mix (Applied Biosystems,
Foster City, CA). The total volume of the resulting solution was made up to 20 µL by nano-pure
RNase free water. All the samples (n = 6/test condition) were processed in duplicates and were
read in ABI 7500 Real Time PCR System (Applied Biosystems). The instrument measured the
fluorescence of SYBR® Green bound to amplified DNA. The gene expression profiles were
analysed using liner regression of efficiency method [156] using a specifically developed
MATLAB code [157]. Gene expression of 18s ribosomal RNA served as an internal control
(house-keeping gene) to normalize the results to report the final DNA copy numbers.
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CHAPTER IV
RESULTS AND DISCUSSION

4.1

Characterization of NPs
As described in chapter 3, the choice of polymer and solvents used, emulsion stirring

rate, and NP fabrication technique (e.g., single- or double-emulsion technique) play a critical role
in determining the size of NPs and the encapsulation efficiency of drugs within [136]. Size and
surface charge characteristics of NPs have been shown to mediate their uptake within various
cell and tissue types. For our long-term application (i.e., aneurysm treatment) we deemed it
essential to generate NPs of hydrodynamic sizes smaller than 500 nm to avoid phagocytic attack,
and greater than 100 nm to avoid immune response [138]. Within this size range, smaller NP
sizes would be preferred, since they would provide the NPs with a higher surface to volume ratio
that would enable enhanced buffer penetration and consequently higher levels of drug release
[158]. Our TGF-β1 loaded NP formulations, surface functionalized with PVA, resulted in sizes
ranging between 296 nm and 352 nm. However, in accordance with other studies, the NP
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formulations generated using DMAB as a surfactant resulted in smaller sized NPs ranging
between 236 and 281 nm [133, 146]. It is important to observe that the NP size tended to
decrease with increasing TGF-β1 loading, and could possibly be attributed to better
compaction/lower porosity of the polymer/drug-matrix and hence lesser swelling in aqueous
media. Studies by Murakami et. al. [159] showed NP swelling ratio (hydrated to dry NP volume)
to correlate with high initial release, which in turn is inversely correlated to active agent loading.
Our release data shown in Section 4.2, agrees with this trend.
PVA, a non-ionic surfactant, is widely adopted in NP formulation to impart an overall
negative surface charge (ζ-potential) and to stabilize the emulsion generated during NP
formulation [160]. The size and ζ- potential for blank NPs and TGF-β1 NPs is listed in the Table
4.1. The average ζ-potential for PVA-functionalized NPs loaded with TGF-β1 was -27.5 mV,
which was comparable to -28 mV ζ–potential, achieved by other publications using PVA
functionalized NPs [161]. The NPs formulated with DMAB as a surfactant expectedly imparted
an overall positive surface charge to the NPs (ζ-potential = +32.2 mV, see Table 4.2), which
would be important from the standpoint of enhancing their arterial uptake [161].
Table 4.1 Data showing size (n = 6), and surface charge (ζ- potential) (n = 6) for blank and TGFβ1-loaded PLGA NPs, surface functionalized with PVA. Also shown are the efficiencies of
encapsulation of TGF-β1 within the NPs (n = 3). Data are represented as mean ± SD.
TGF-β1 loaded NPs

Blank NPs
1 µg

2 µg

5 µg

Size (nm)

275.6 ± 28.8

295.8 ± 5.1

351.7 ± 9.9

347.4 ± 40.3

ζ- potential (mV)

-30.3 ± 2.3

-28.1 ± 2.0

-25.5 ± 2.8

-25.9 ± 3.0

Encapsulation
efficiency (%)

NA

85.7 ± 1.2

73.8 ± 14.6

91.4 ± 3.0
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Table 4.2 Data showing size (n = 6), surface charge (ζ- potential) (n = 6) and efficiencies of
encapsulation of TGF-β1 within the NPs (n = 1), surface functionalized with DMAB. Data are
represented as mean ± SD.
TGF-β1 loaded NPs
0.1 µg

0.2 µg

0.3 µg

Size (nm)

280.5 ± 11.4

265.5 ± 18.5

236.3 ± 5

ζ- potential (mV)

32.9 ± 2.2

30.1 ± 4.1

33.5 ± 2.5

Encapsulation efficiency (%)

68.3

74.5

81.2

The encapsulation efficiency of TGF-β1 NPs was calculated by estimating the amount of
unencapsulated TGF-β1 in the supernatants obtained upon pelleting TGF-β1 encapsulated NPs
by ultracentrifugation. Our studies demonstrated high encapsulation efficiencies for both PVAand DMAB-formulated NPs. After subtracting the estimated amount from the initially loaded
TGF-β1, the overall encapsulation efficiency ranged between 74 ± 15 % and 91 ± 3% for PVAformulated NPs, while they ranged between 68.3 % and 81.2 % for DMAB-functionalized NPs.
These encapsulation efficiencies are high compared to other studies encapsulating TGF-β1
within micro-particles, which reported entrapment efficiencies of 25-50% [162, 163].

4.2

Release of TGF-β1 from PLGA NPs
Nanoparticles loaded with active agents release the drug first upon hydrolytic surface

degradation and later, through aqueous infiltration into NP matrix, followed by bulk diffusion.
Methods like HPLC [164], and UV-spectrophotometry [165] are used for in vitro detection of the
NP-released active drugs in aqueous reservoirs. When growth factors are instead encapsulated
within nanoparticles and microparticles, their release is detected or quantified using ELISA [144,
52

160]. This technique has the advantage of being highly specific for detecting proteins of interest.
In this study, the amounts of TGF-β1 detected at various time points were plotted together to
obtain a cumulative TGF-β1 release curve, as shown in Figures 4.1 and 4.2.

Figure 4.1 Cumulative release curves of TGF-β1 from NPs loaded with TGF-β1 over 21 days,
surface functionalized with DMAB (n = 1). A) Represents the absolute amounts of TGF-β1
released by NPs in 1 mL of release media; B) Represents the percentage release of encapsulated
TGF-β1 in NPs

TGF-β1 was released from 0.4 mg/mL concentration of NPs formulated with DMAB, in
PBS and quantified using ELISA. As illustrated in Figure 4.1, the overall TGF-β1 released over
the period of 21 days was approximately 2.5% of the total TGF-β1 encapsulated. It should be
noted that the release was higher in NPs with lower TGF-β1 loading density (0.1 µg). The
cumulative release curves appeared biphasic as others have also shown with other active agents
released from PLGA NPs [159]. A high initial burst of approximately 1 ng in the first 24 h
followed by a flattening ‘lag’ phase, and further followed by a second phase on relatively rapid
increase at day 15. The initial burst is attributable to release of physically adsorbed drug on the
NP surface, and the delayed release phase to release of covalently bound/entrapped drug within
the PLGA matrix released as the NP degrades. Despite this encouraging result, a problem
encountered was that DMAB contributes to false positive detection of TGF-β1 via ELISA. For
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Figure 4.2 Cumulative release curves of TGF-β1 from NPs loaded with TGF-β1 over 21 days,
surface functionalized with PVA (n = 3). A) Represents the absolute amounts of TGF-β1
released by NPs in 1 mL of release media; B) Represents the percentage release of encapsulated
TGF-β1 in NPs

example, a 0.01% w/v DMAB solution in PBS was read as equivalent to 0.35 ng of TGF-β1,
when processed on the ELISA plate. Due to this, it led into artificial ramping up of TGF-β1
detected. Thus, the amount of TGF-β1 released from DMAB-PLGA NPs as estimated by ELISA,
was deemed unreliable. On this account, the DMAB-NPs were deemed unsuitable for use in
subsequent cell culture experiments, wherein the provided TGF-β1 dose would required to be
known. Differently, we did not observe any such false positive detection of TGF-β1 when a
solution containing 0.01% w/v PVA was subjected to ELISA. Accordingly, the effects of NPreleased TGF-β1 on cells were further investigated using only PLGA-NPs formulated with PVA.
Considering the lower detection limit and high specificity of ELISA technique for TGF-β1,
TGF-β1 released from a 10 mg/mL NP suspension in PBS was in the detectable range of the
commercially purchased ELISA kit. The highest release of TGF-β1 (6.8 ± 0.1 ng in release
media) was detected from NPs loaded with 2 µg of TGF-β1, which was equivalent to 0.5% of
total TGF-β1 encapsulated in the NPs. The overall release of TGF-β1 was deemed low and
accordingly none of the TGF-β1 loadings, however, was found to release the equivalent of 1.0
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ng/mL over 2 days to match the exogenous TGF-β1 dose shown by our group to have
elastogenic effects in previous publications [16]. The release of TGF-β1 from the PLGA NPs
could potentially be limited due to the high molecular weight of PLGA (117 kDa), or its high
lactide content (50%), both of which could prolong degradation and hence release of active
agent. Future studies will seek to modulate these parameters to be able to enhance TGF-β1
release levels as required.

4.3

Bioavailability and Structural integrity of released TGF-β1
The structural integrity of NP-released TGF-β1 was confirmed by comparing its co-

localization with a band generated by exogenous, un- encapsulated TGF-β1 on a western blot gel
and detected using an anti-TGF-β1 antibody. The bands corresponding to NP-released TGF-β1
and exogenous TGF-β1 were both detected and migrated the same down a polyacrylamide gel
(see Figure 4.3) demonstrating that released TGF-β1 did not undergo any structural changes and

Figure 4.3 Western blots of released TGF-β1 (25 kDa). Lanes A and B (duplicates) contain
TGF-β1 before entrapment; lanes C and D contain TGF-β1 released from NPs; and lanes E and F
contain release media from Blank NPs.
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fragmentation. It is important to note that the bands of released TGF-β1 are brighter than the 1
ng/lane positive control bands, suggesting a fairly high TGF-β1 release in a 24 hour period,
which we also deemed from ELISA measurements.

4.4

Bioactivity of released TGF-β1 in Mink Lung Cell cultures
It has been shown that TGF-β1 inhibits the proliferation of cells derived from epithelial,

endothelial, hematopoietic, and neural tissues [150]. More specifically, 100 pM TGF-β1,
equivalent to a concentration of ~3.0 ng/mL, has been reported to significantly inhibit the
proliferation of mink lung cells (MLCs) in culture [150]. We sought to assess the inhibitory
effects of TGF-β1 released from NPs on MLCs, to confirm its continued biofunctionality/activity.
As described in Section 3.3, the MLC cultures were dosed with TGF-β1 NPs at a
concentration of 0.5 mg/mL. Their effects were compared with separate cultures wherein blank
NPs were provided at the same concentration and a known non-inhibitory dose (0.03 ng/mL,
equivalent to 1 pM) of exogenous TGF-β1. In addition to these negative controls, there was an
untreated treatment condition as well. Cultures dosed with known inhibitory TGF-β1 dose (3.0
ng/mL) served as a positive control. Our experiment showed cell counts for the non-additive
treatment condition, non-inhibitory dose of exogenous TGF-β1, and blank NP-treatment
conditions to not differ at allassay time points (days 1, 4 and 7 post-seeding). While untreated
MLCs at day 7 showed 3.2 ± 0.2-fold increase in number compared over initially seeded cell
counts, cells treated with 3.0 ng/mL of exogenous TGF-β1 exhibited a more limited 2.2 ± 0.1fold increase. This suppressive effect of MLC numbers upon treatment with exogenous TGF-β1
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(100 pM or 3.0 ng/mL) relative to untreated controls was maintained at all studied time points, as
shown in Figure 4.4. In case of MLCs treated with TGF-β1 loaded NPs, the effects were not as
pronounced as the 100 pM exogenous TGF-β1-treatment condition, but significantly different (p
< 0.001) than outcomes observed in the negative controls and blank NP treated condition. There
was only 1.4 ± 0.1 fold increase in cell counts cultures treated with TGF-β1 releasing NPs with

Figure 4.4 Effect of TGF-β1 and control treatment conditions on proliferation of MLCs, seeded
at 12 × 104cells per well (n = 6 wells/case). Results shown represent mean ± SD of fold increases
in cell number relative to that at seeding. Significant differences versus untreated and blank NP
treated cultures are indicated as * and + respectively, and was deemed for p < 0.05.

after 1 day of exposure, relative to 1.7 ± 0.1 (p < 0.001) fold increase observed for the no
treatment cultures, and 1.6 ± 0.1 (p < 0.011) fold increase for the blank NP supplemented
cultures. The suppressive effects of NP-released TGF-β1 on MLC proliferation were maintained
at longer time points also. This clearly demonstrates the inhibitory effects of released TGF-β1 on
MLCs. Conclusively, this experiment showed the existence of active TGF-β1 released from NPs
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and the inhibitory effects were attributed as measure of its bio-functionality, released in cell
culture media.

4.5

Lack of cytotoxic effects of TGF-β1 NPs on EaRASMCs
The concentration-dependent cytotoxicity of PLGA NPs loaded with TGF-β1 was

assessed using a LIVE/DEAD® viability assay kit as described in Section 3.4.2. The assay
components include calcien AM that stains viable cells to fluoresce green, while ethidium
homodimer-1 (Ethd1) stains dead cells to fluoresce red. The mechanism of this assay is
dependent on intracellular esterase activity of cells which enzymatically converts the calcein AM
to flurorescent calcein, and Ethd1 permeates through membranes of dead cells to bind to the
nucleic acids and undergo 40-fold fluorescence enhancement.
The representative images obtained after LIVE/DEAD® assay carried out on EaRASMC
cultures using NPs loaded with TGF-β1 at concentrations (0.1, 0.2, 0.5 and 1 mg/mL and
untreated control) are shown in Figure 4.5. The LIVE/DEAD assay outcomes showed 99 ± 1.8%
of cells to be viable when cultures were treated with NPs at concentrations 0, 0.1, 0.2 and 0.5
mg/mL. For NP concentration of 1.0 mg/mL, cell viability was 97.8 ± 3.4%, which was however,
not significantly different from a statistical standpoint from cultures treated with lower NP doses.
Based on these outcomes, we confirmed that cell culture studies conducted with an NP
concentration of 0.5 mg/mL, would not adversely impact cellular health and viability.

58

A

No NPs

B

C

0.1 mg/ mL

0.2 mg/mL

D

E

0.5 mg/mL

1.0 mg/mL

Figure 4.5 Results from LIVE/DEAD® assay. Viabilities in all cultures, treated and untreated
were > 99%, except for 1.0 mg/mL of NPs (E) where it was ~ 97%

4.6

Effect of TGF-β1 release from NPs on EaRASMC proliferation
The fluorometric DNA assay was carried out on cell layers harvested on day 0 samples

and day 21 samples for all the treatment conditions, as described in Section 3.5.1. The average
cell counts at day 0 were (3.3 ± 0.6) × 104 cells per well (n = 6 per test case).
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The average fold increase in cell number at the end of 21 days compared to initial adhered cell
counts for all the treatment conditions was 4.1 ± 0.4. It must be noted that the cell counts
obtained from exogenous TGF-β1 and TGF-β1 NP treatment conditions were significantly lower
than the untreated condition (p << 0.001), as shown in Figure 4.6. This result could be attributed
to the ability of TGF-β1 to arrest the proliferation of EaRASMCs, which could be useful to
attenuate potential hyper-proliferation of activated SMCs involved in tissue remodeling at the
AAA sites, when the TGF-β1 NPs are ultimately delivered as therapy [116, 166].

Figure 4.6 Results of DNA assay showing EaRASMCs count initially seeded and after 21 days
of treatment with NPs loaded with TGF-β1 and other control test conditions. Shown are the
mean ± SD of counts determined from n = 6 cultures/case. Significance of differences versus the
no treatment conditions and blank NPs at 21 days are indicated as * and + respectively, and was
deemed for p < 0.05.

60

4.7

Matrix Assays

4.7.1

Fastin Assay
The quantification of elastin deposited by EaRASMCs upon exposure to NPs loaded with

TGF-β1 and other control cases was estimated using a Fastin assay, as described in Section
3.5.2. The results from these studies for all the treatment conditions are illustrated in Figure 4.7.
As described earlier, the TGF-β1 released from NPs was considerably lower than the
exogenous dose of 1.0 ng/mL TGF-β1, which was previously shown to mediate elastogenic
induction of EaRASMCs [116]. As a result, the amounts of alkali-insoluble elastin generated in
cultures of treated with TGF-β1 loaded NPs were not significantly higher compared to the other
treatment conditions/controls (Figure 4.7). The alkali-insoluble, highly cross-linked elastin in
NP-untreated cultures were 2.03 ± 0.6 µg per well, while in case of cells treated with TGF-β1releasing NPs, it was about 1.96 ± 0.1 µg. In the case of alkali-soluble elastic matrix fraction,
exogenous TGF-β1 and NP-released TGF-β1 attenuated deposition, though in the latter case,
soluble elastic matrix amounts were not significantly different from the untreated control
cultures. The decrease in soluble-elastin expression/deposition in the exogenous TGF-β1-treated
case is likely due to TGF-β1 doses being at least 10 fold lower relative to doses previously
identified as elastogenic, by our lab (1.0 ng/mL of TGF-β1) [16, 116]. This lower exogenous
dose was delivered here since it matched the amount of TGF-β1 we determined to be released by
NPs. Since TGF-β1 exhibits biphasic effects, depending on provided dose, it is quite possible
that the TGF-β1 dose delivered in this study (~1 ng/mL over 21 days) to cells did not specifically
induce elastogenic effects and contrarily, inhibited elastic matrix production. One interesting
observation was that on a per cell basis, total matrix elastin
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Figure 4.7 Alkali-soluble and –insoluble elastic matrix deposition by EaRASMCs over 21 days
of culture, as represented on a per cell basis. Shown results represent mean ± SD of values
obtained by analysis of n = 6 cultures/case. * represents significance of difference versus control
(no treatment) cultures, deemed for p < 0.05.
production was slightly higher in blank NP-treated cultures than in untreated cultures. Although
the differences were ultimately deemed statistically not significant, the results suggest that even
the blank NPs may have a positive effect on elastic precursor recruitment for crosslinking, which
could potentially be attributed to their negative surface charge, which could ‘capture’ and
facilitate coacervation/nucleation of the tropoelastin precursors for further cross-linking.

4.7.2

Hydroxy-Proline Assay
The OH-Pro assay estimates the amount of collagen deposits in the ECM of harvested

cultures by quantifying amount of OH-Pro residues. The OH-Pro assay on the untreated,
exogenous TGF-β1 NPs and treated with blank NPs did not show significant difference to their
overall collagen content. However, the cultures treated with NPs loaded with TGF-β1 showed
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elevated levels of collagen in their ECM, which were significantly higher (p << 0.01) compared
to the other treatment conditions. Elevated amount of collagen in TGF-β1-NP treated culture can
be attributed to a well-established pro-fibrotic response by EaRASMCs, wherein their
expression/production of collagen [167, 168] and α-SMA [168] has been documented. The lack
of similar effects in cultures supplemented with exogenous TGF-β1 at concentration equivalent
to release achieved from the NPs, and the lack of any effect, positive or negative, with use of
blank NPs suggests that a) blank NPs surface modified with PVA do not provide any physical or
charge-mediated benefits to collagen precursor capture and/or matrix assembly unlike their
effects on elastic matrix assembly, and b) controlled and steady delivery of TGF-β1 from NPs to
cell cultures could provide benefits over delivery of soluble growth factors. The latter aspect

Figure 4.8 Collagen matrix deposition by EaRASMCs over 21 days of culture, using the OH-Pro
assay and shown on a per cell basis. Shown are the mean ± SD of amounts determined from
assay of n = 6 cultures/case. * represents significance of differences versus TGF-β1 NP-treated
cultures, deemed for p < 0.05.
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could be due to relatively rapid soluble deactivation/loss of activity of exposed, exogenous TGFβ1 and its transient engagement of all surface receptors as others have suggested with other
biomolecular factors [169]. The lack of such effects with NPs may be due to their providing a
protective matrix encapsulating TGF-β1 intactly until it is released.

4.8

Immunofluorescence detection of elastin, fibrillin-1 and LOX
As described in Section 3.6, immunofluorescence detection was carried out via confocal

microscopy on the paraformaldehyde-fixed, 21-day cell layers, to qualitatively compare
deposition of elastin and fibrillin-1, and expression of LOX in cultures that were untreated, or
treated with exogenous TGF-β1, blank NPs, and TGF-β1-NPs. For this study, three images were
taken from different areas in the same culture well. The representative IF images obtained from
each of the culture cases are shown in Figures 4.9, 4.10 and 4.11, respectively for elastin,
fibrillin-1 and LOX.
IF images were obtained from 8 µm thickcell layer sections. The sections were imaged at
1 µm thickness intervals and the images were overlaid to create a z-stack composite. These
images showed sufficient signal for elastin in all of the treatment conditions. However, cell
layers treated with TGF-β1 exhibited elastic matrix that appeared better organized than control
cell layers and those treated with blank NPs. IF images shown in Figure 4.9 exhibit trends in
elastic matrix deposition that mimic trends indicated by the Fastin assay results. Elastin
deposition in exogenous TGF-β1-supplemented cultures appeared to be the least of the four
tested cases. Further, in this culture case, most of the elastin appeared to be intracellularly
distributed with few visible extracellular structures. As also seen in the results of Fastin assay,
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the most intense staining for elastin in the cell layers were in cultures treated with the blank NPs
and TGF-β1-releasing NPs, where the elastin was significantly distributed in the extracellular
space and showed greater organization relative to the exogenous TGF-β1-added cultures and
untreated controls.
IF labeling for fibrillin-1 indicated significantly increased expression in cultures treated
with TGF-β1-releasing NPs, compared to any of the other treatments. The expression of fibrillin1 was localized close to the EaRASMC nuclei especially in control cultures but was far more
apparent in the extracellular space for the other treatments, particularly cultures containing TGFβ1 NPs and exogenous TGF-β1, in places exhibiting a beads-on-string appearance, which is due
to in vitro polymerization of fibrillin monomers [170]. These findings are consistent with
previously published reports that have shown TGF-β1 to enhance fibrillin-1 secretion and
deposition in cardiac fibroblast cultures [171], and to enhance fibrillin protein synthesis in the
ECM of sclerotic skin [172]. Further, previous studies in our own lab have shown TGF-β1 to
upregulate fibrillin-1 deposition and hence elastic fiber formation by vascular SMCs [16]. It was
also noted that the cultures/treatments that exhibited the greatest fluorescence due to fibrillin-1
(TGF-β1 NPs) also exhibited the greatest amounts of elastic matrix deposition, suggesting that
enhancing fibrillin deposition will improve elastic matrix assembly.
Previous studies have shown TGF-β1 to upregulate gene expression synthesis of lysyl
oxidase (LOX), a protein/enzyme involved in crosslinking elastin precursors into an alkaliinsoluble matrix [173]. Data generated in our lab, have mirrored these findings [16]. In our
study, we observed that TGF-β1, both exogenous and when released from PLGA NPs,
significantly enhanced LOX protein synthesis by EaRASMC versus untreated EaRASMC
cultures. Despite some increases in LOX protein synthesis by NP-released TGF-β1 (and
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No treatment

Exogenous TGF-β1

Blank NP

TGF-β1 NPs

Figure 4.9 Representative images of controls and TGF-β1 and/or NP-treated EaRASMC cultures
IF-labeled for elastin (pink) at 21 days of exposure. DAPI-labeled nuclei appear blue.
Magnification: 20×. Scale bars represent 50 µm.
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No treatment

Exogenous TGF-β1

Blank NP

TGF-β1 NPs

Figure 4.10 Representative images of controls and TGF-β1 and/or NP-treated EaRASMC
cultures IF-labeled for fibrillin-1 (pink) at 21 days of exposure. DAPI-labeled nuclei appear blue.
Magnification: 20×. Scale bars represent 50 µm.
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No treatment

Exogenous TGF-β1

Blank NP

TGF-β1 NPs

Figure 4.11 Representative images of controls and TGF-β1 and/or NP-treated EaRASMC
cultures IF-labeled for LOX (pink) at 21 days of exposure. DAPI-labeled nuclei appear blue.
Magnification: 20×.Scale bars represent 50 µm.

exogenous TGF-β1), we did not see any dramatic increase in deposited elastic matrix relative to
untreated controls. This may be attributed to two factors. The first, mentioned earlier, may be
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due to the low delivered doses of TGF-β1, which were about 1/10th of the elastogenic doses
previously identified [16]. The second factor is the inhibiting effect of the negative charge (-27.5
± 2.2 mV) on the PLGA surface, imparted by the PVA surface modification, on the LOX
activity. Studies from the 1970s showed that negatively charged amphiphiles attenuate LOX
activity while cationic amphiphiles enhance the same [174]. In separate studies, our lab has
shown cationic amphiphiles (e.g., DMAB) used as surfactant for creating PLGA NPs to enhance
LOX activity in healthy RASMC cultures. Thus, despite the potential enhancement of LOX
protein synthesis by TGF-β1, the negative surface charge on the NPs may provide a dampening
effect (attenuating), resulting lower detection of active LOX protein. On this basis, in future
studies, we plan to surface functionalize TGF-β1 loaded NPs with agents other than DMAB,
which impart a positive charge to be able to enhance LOX activity for increased elastin precursor
cross-linking and matrix generation.

4.9 Western Blotting for LOX
The results from western blots on cell samples treated with treatment conditions
mentioned in Section 3.7 are illustrated in Figure 4.12. The 32 kDa active-LOX protein band
was observed to align with the LOX standard in the same gel. We also found substantially bright
bands aligning in the molecular weight of ~28 kDa, which could be the 28 kDa LOX protein
cleavage product [175].
This result suggests the presence of LOX protein qualitatively, and supports the findings
of existence of LOX protein deposition visualized in IF studies. The LOX protein bands were
quantified using Image J software based on their intensities, and were normalized to band
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intensities of β-actin, which served as protein loading controls for each test condition. As
illustrated in Figure 4.13, we found that cells treated with non-additive treatment deposited the
least amount of LOX, based on band intensities. The results were represented as fold change for
each test condition, with respect to results obtained in case of untreated controls cultures. Cells
treated with exogenous TGF-β1 produced about 1.9 fold greater LOX, while cells treated with
NPs loaded with TGF-β1 deposited 1.6 fold greater LOX, compared to the non-additive
treatment condition.

Figure 4.12 Western blot results for LOX (32 kDa - active protein, 28 kDa - cleaved LOX
product); lane A contains protein from non-additive treated, lane B contains exogenous TGF-β1
treated, lane C contains blank NP treated and lane D contains TGF-β1 NP treated condition.

Figure 4.13 Quantification of LOX-protein band intensities, normalized to band intensities of βactin as visualized in western blots. * represents significant difference (p < 0.05) compared to
band intensities in TGF-β1 treated cultures.
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4.10

RT-PCR analysis for elastin and elastic matrix assembly proteins
The gene expression of proteins expressed as an effect of treatment of TGF-β1 released

from the NPs was compared to the TGF-β1-untreated condition, using RT-RCR. The mRNAs
served to reverse transcribe the cDNAs and gene expressions of elastin, collagen type-1, fibrillin1, LOX, and fibulin-5 were examined. The expression of 18S served as inherent control. All the
gene expression levels were normalized to that of 18S, and differences in such normalized gene
expressions (expressed as relative fluorescence units or RFUs) between controls and TGF-β1-NP
supplemented cultures shown in Figure 4.14. The results indicate collagen gene expression to be
approximately two times in cultures treated with TGF-β1 NPs compared to untreated treatment
condition, which was statistically significant. These results also align with results of the OH-Pro
assay that showed increase in collagen matrix amounts in cultures treated with the TGF-β1 NPs.
The results also indicated LOX up-regulation in TGF-β1 NP treated cultures reinforcing the
semi-quantitative LOX western blot outcomes and the synthesis of LOX observed via IF studies.
These results indicate the presence and up-regulation of structural proteins and LOX enzyme
which are crucial to the process of synthesizing elastin fibers in ECM of EaRASMC cultures.
However, the TGF-β1 NP treated cultures exhibited lower levels of mean elastin gene
expression, but as described earlier, could be potentially attributable to lower doses of TGF-β1
released from NPs, compared to dosages previously examined by our lab [16, 116]. The gene
expression of fibrillin-1 and fibulin-5 were not deemed as significantly different. Future studies
focusing to determine higher TGF-β1 dosage released from NPs, comparable to exogenous and
elastogenic TGF-β1 dosage identified previously, could potentially generate higher elastin gene
expression, significantly different from the controls.
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Figure 4.14 Gene expression of proteins of interest represented as RFU from TGF-β1 NP treated
and untreated cultures. Shown are the results as mean ± SD of the RFU for different proteins. *
represents the gene expression differed significantly between TGF-β1 NP treated and untreated
cultures (p < 0.01)
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CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS

5.1

Conclusions
Our studies demonstrate successful encapsulation of recombinant human TGF-β1 in

PLGA NPs. We were able to generate TGF-β1 encapsulated NPs exhibiting the desirable average
hydrodynamic sizes ranging between 300 to 400 nm, when surface functionalized with both,
PVA and DMAB. The TGF-β1 loaded NPs, surface modified with PVA exhibited high TGF-β1entrapment efficiencies, between 74 ± 15% and 91 ± 3%, depending on TGF-β1 amounts loaded
per mg of NPs. Similarly, the DMAB-NPs too exhibited high TGF-β1 entrapment efficiencies
between 64% and 81%. Muller et. al. have reported that electrostatic repulsions due to surface
charge (±30 mV) result in stable nano-suspensions [134]. Thus, the overall significant negative
surface charge (-27.5 mV) of the NPs surface functionalized with PVA, measured as ζ-potential;
while positively surface charged TGF-β1 DMAB-NPs exhibited an average of+ 32.2 mV, both,
indicated the stable NP formulation and a deterrent to NP aggregation [176]. Summarizing the
properties/characteristics of NPs, our NP formulations showed characteristics deemed desirable
in terms of size, charge and encapsulation efficiencies of TGF-β1.
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Our western blot studies confirm that the TGF-β1 released from PVA-NPs maintains
structural integrity, since it generates a protein band that co-localizes with protein bands
generated with recombinant TGF-β1 standards. Additionally, our experiments showed the TGFβ1 released from PVA-NPs to remain bioactive since it significantly inhibited the proliferation of
cultured mink lung epithelial cells (MLCs). We also determined the pattern of release of TGF-β1
as PLGA NP shell degrades via hydrolysis in PBS system. When PVA-NPs or DMAB-NPs
encapsulating TGF-β1 were suspended in PBS, the TGF-β1 was released with a high initial burst
followed by the ‘lag’ phase, exhibiting a steady state release of the protein, which was
maintained over at least 21 days. However, as described in previous sections, release from
DMAB-NPs exhibited artificial ramping up of released TGF-β1 due to false positive detection of
DMAB using ELISA. Future studies will employ alternative detection techniques (e.g., HPLC)
to overcome this problem and utilize the positively surface charged NPs on account of their
enhanced arterial uptake and affinity to recruit negatively charged LOX.
Even though the TGF-β1-loaded PVA-NPs released less than 1.0 ng of TGF-β1 in a 2
day period, a dose we showed previously to be elastogenic, IF images demonstrated higher
expression and deposition of elastin in the ECM of EaRASMCs and in a more organized
pattern/form in NP- TGF-β1 treated cultures. Also, they showed higher expression of fibrillin-1,
which helps as a scaffolding skeleton for elastin deposition, and LOX, which helps in crosslinking of soluble elastin molecules in TGF-β1-NP treated cultures when compared to untreated
and other control cultures. Semi-quantitative analysis by western blots revealed significantly
high amount of LOX presence in NP-TGF-β1 treated cultures compared to untreated cultures.
The amount of collagen deposition in TGF-β1 NP-treated cultures was also observed to be about
3-fold compared to any other treatment condition, as quantitatively deemed by OH-Pro assay.
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These observations were supported by observed upregulated gene expression of collagen, and
LOX with respect to untreated cultures, although elastin gene expression was not significantly
different from control cultures. The lack of upregulation of elastin gene expression was
consistent with lack of increases in elastic matrix deposition in the cultures treated with TGF-β1loaded NPs compared to untreated and cultures treated with blank NPs, as demonstrated by
Fastin assay. Thus, any improvement in elastic matrix deposition, as gauged using IF, was likely
due to improved crosslinking of elastin precursors by LOX, which was seen to be upregulated by
TGF-β1-NPs both at the gene and protein levels.

5.2

Future Recommendations
The continued studies pertaining to elastogenic induction due to TGF-β1 released from

NPs in future will focus on the optimization of several factors from the outcomes of our present
study. Few recommendations that can prove fruitful and improve the overall goal of this project
are described as follows:
1. Utilize HPLC or other methods to measure release of TGF-β1 from DMAB-NPs, the
positively charged NPs which are more useful from the stand-point of arterial uptake.
Additionally, this will enable us to measure fresh TGF-β1 released at each time point
versus frozen aliquots of TGF-β1, collected over time.
2. Formulate NPs with low molecular weight PLGA or PLGA containing higher glycolide
content to accelerate the release of TGF-β1 towards ultimately achieving higher release
over the period of 21 days.
3. Scanning electron microscopy (SEM) of NPs at different time points over 21 days to
understand the degradation of PLGA NPs from morphological perspective.
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4. Desmosine-isodesmosine assay to assess the level of crosslinking in newly formed elastic
matrix of cell cultures.
5. Test other cationic amphiphiles as alternatives to DMAB (e.g., Dodecyltrimethyl
ammonium bromide (DTAB), Dodecylamine hydrochloride (DAH)) to impart positive
charge to NPs for providing better arterial uptake.
6. Investigate physical implications of NPs: crowding effect on ECM deposition
7. Assess uptake and bio-distribution of NPs in rat aortae, binding to elastic matrix
structures, and delivery strategies (i.e., intraluminal infusion with a drug delivery catheter
or peri-adventitial injection.
8. Test elastogenic effects if concurrent delivery of HA-o and TGF-β1 releasing NPs.
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